JP2005336168A - 4−アミノ−5−シアノピリミジン誘導体 - Google Patents
4−アミノ−5−シアノピリミジン誘導体 Download PDFInfo
- Publication number
- JP2005336168A JP2005336168A JP2005125880A JP2005125880A JP2005336168A JP 2005336168 A JP2005336168 A JP 2005336168A JP 2005125880 A JP2005125880 A JP 2005125880A JP 2005125880 A JP2005125880 A JP 2005125880A JP 2005336168 A JP2005336168 A JP 2005336168A
- Authority
- JP
- Japan
- Prior art keywords
- group
- amino
- lower alkyl
- compound
- saturated heterocyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JAIYUIOGVNRXEW-UHFFFAOYSA-N 4-aminopyrimidine-5-carbonitrile Chemical class NC1=NC=NC=C1C#N JAIYUIOGVNRXEW-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 45
- -1 methylenedioxy group Chemical group 0.000 claims description 398
- 125000000217 alkyl group Chemical group 0.000 claims description 189
- 125000000623 heterocyclic group Chemical group 0.000 claims description 114
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 89
- 125000003118 aryl group Chemical group 0.000 claims description 86
- 125000001072 heteroaryl group Chemical group 0.000 claims description 46
- 125000001424 substituent group Chemical group 0.000 claims description 40
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 39
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 36
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 35
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 30
- 125000003545 alkoxy group Chemical group 0.000 claims description 29
- 125000003277 amino group Chemical group 0.000 claims description 28
- 229910052757 nitrogen Inorganic materials 0.000 claims description 25
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 24
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 23
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 125000005843 halogen group Chemical group 0.000 claims description 18
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 18
- 125000005090 alkenylcarbonyl group Chemical group 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 125000002947 alkylene group Chemical group 0.000 claims description 16
- 125000003282 alkyl amino group Chemical group 0.000 claims description 15
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 15
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 14
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 13
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 12
- 125000004104 aryloxy group Chemical group 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 125000004043 oxo group Chemical group O=* 0.000 claims description 10
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 7
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 7
- 125000002944 cyanoaryl group Chemical group 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000004450 alkenylene group Chemical group 0.000 claims description 6
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 6
- 125000004419 alkynylene group Chemical group 0.000 claims description 6
- DMDJTLNTJHFQMG-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[3-[4-[2-(diethylamino)ethyl]piperazin-1-yl]-3-oxopropyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide Chemical compound C1CN(CCN(CC)CC)CCN1C(=O)CCC1=CC=CC(CSC=2N=C(C(C#N)=C(N)N=2)C=2C=CC(NC(C)=O)=CC=2)=N1 DMDJTLNTJHFQMG-UHFFFAOYSA-N 0.000 claims description 6
- 125000004171 alkoxy aryl group Chemical group 0.000 claims description 4
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 4
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 125000005001 aminoaryl group Chemical group 0.000 claims description 4
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 4
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims description 4
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 4
- WIIFGKRAHUIRLZ-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-(pyridin-2-ylmethylsulfanyl)pyrimidin-4-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=NC(SCC=2N=CC=CC=2)=NC(N)=C1C#N WIIFGKRAHUIRLZ-UHFFFAOYSA-N 0.000 claims description 4
- RZNKYVLELCTRGG-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[(6-methylpyridin-2-yl)methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=NC(SCC=2N=C(C)C=CC=2)=NC(N)=C1C#N RZNKYVLELCTRGG-UHFFFAOYSA-N 0.000 claims description 4
- KEJUGYGPEARNCU-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[3-(4-methylpiperazin-1-yl)-3-oxopropyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide Chemical compound C1CN(C)CCN1C(=O)CCC1=CC=CC(CSC=2N=C(C(C#N)=C(N)N=2)C=2C=CC(NC(C)=O)=CC=2)=N1 KEJUGYGPEARNCU-UHFFFAOYSA-N 0.000 claims description 4
- LRBGBRSXOGPAJK-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[3-[2-[(4-ethylpiperazin-1-yl)methyl]morpholin-4-yl]-3-oxopropyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide Chemical compound C1CN(CC)CCN1CC1OCCN(C(=O)CCC=2N=C(CSC=3N=C(C(C#N)=C(N)N=3)C=3C=CC(NC(C)=O)=CC=3)C=CC=2)C1 LRBGBRSXOGPAJK-UHFFFAOYSA-N 0.000 claims description 4
- WWDBSNBJXSXIDR-UHFFFAOYSA-N 3-[6-[[4-(4-acetamidophenyl)-6-amino-5-cyanopyrimidin-2-yl]sulfanylmethyl]pyridin-2-yl]-n-[2-(dimethylamino)ethyl]-n-methylpropanamide Chemical compound CN(C)CCN(C)C(=O)CCC1=CC=CC(CSC=2N=C(C(C#N)=C(N)N=2)C=2C=CC(NC(C)=O)=CC=2)=N1 WWDBSNBJXSXIDR-UHFFFAOYSA-N 0.000 claims description 3
- MPPWHKGQYJQZTJ-UHFFFAOYSA-N 3-[6-[[4-(4-acetamidophenyl)-6-amino-5-cyanopyrimidin-2-yl]sulfanylmethyl]pyridin-2-yl]-n-[2-(dimethylamino)propyl]-n-methylpropanamide Chemical compound CN(C)C(C)CN(C)C(=O)CCC1=CC=CC(CSC=2N=C(C(C#N)=C(N)N=2)C=2C=CC(NC(C)=O)=CC=2)=N1 MPPWHKGQYJQZTJ-UHFFFAOYSA-N 0.000 claims description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 3
- 125000001769 aryl amino group Chemical group 0.000 claims description 3
- 125000005163 aryl sulfanyl group Chemical group 0.000 claims description 3
- PISPDKYRNUXUJP-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[3-(4-methyl-1,4-diazepan-1-yl)-3-oxopropyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide Chemical compound C1CN(C)CCCN1C(=O)CCC1=CC=CC(CSC=2N=C(C(C#N)=C(N)N=2)C=2C=CC(NC(C)=O)=CC=2)=N1 PISPDKYRNUXUJP-UHFFFAOYSA-N 0.000 claims description 3
- ZGCJWZHRDZWQGN-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[3-[4-(2-morpholin-4-ylethyl)piperazin-1-yl]-3-oxopropyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=NC(SCC=2N=C(CCC(=O)N3CCN(CCN4CCOCC4)CC3)C=CC=2)=NC(N)=C1C#N ZGCJWZHRDZWQGN-UHFFFAOYSA-N 0.000 claims description 3
- YWEOAQVARVIPEP-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[3-[4-[2-[di(propan-2-yl)amino]ethyl]piperazin-1-yl]-3-oxopropyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide Chemical compound C1CN(CCN(C(C)C)C(C)C)CCN1C(=O)CCC1=CC=CC(CSC=2N=C(C(C#N)=C(N)N=2)C=2C=CC(NC(C)=O)=CC=2)=N1 YWEOAQVARVIPEP-UHFFFAOYSA-N 0.000 claims description 3
- PNFUCXHMSWYMCS-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[3-oxo-3-(4-piperidin-1-ylpiperidin-1-yl)propyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=NC(SCC=2N=C(CCC(=O)N3CCC(CC3)N3CCCCC3)C=CC=2)=NC(N)=C1C#N PNFUCXHMSWYMCS-UHFFFAOYSA-N 0.000 claims description 3
- LZYHBQFHIZQCML-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[3-oxo-3-[2-(piperidin-1-ylmethyl)morpholin-4-yl]propyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=NC(SCC=2N=C(CCC(=O)N3CC(CN4CCCCC4)OCC3)C=CC=2)=NC(N)=C1C#N LZYHBQFHIZQCML-UHFFFAOYSA-N 0.000 claims description 3
- FJJDNXSJBDQQKA-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[3-oxo-3-[4-(2-pyrrolidin-1-ylethyl)piperazin-1-yl]propyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=NC(SCC=2N=C(CCC(=O)N3CCN(CCN4CCCC4)CC3)C=CC=2)=NC(N)=C1C#N FJJDNXSJBDQQKA-UHFFFAOYSA-N 0.000 claims description 3
- RUJSMXHQJJNKTO-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[[4-[2-(4-methylpiperazin-1-yl)acetyl]piperazin-1-yl]methyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide Chemical compound C1CN(C)CCN1CC(=O)N1CCN(CC=2N=C(CSC=3N=C(C(C#N)=C(N)N=3)C=3C=CC(NC(C)=O)=CC=3)C=CC=2)CC1 RUJSMXHQJJNKTO-UHFFFAOYSA-N 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000005027 hydroxyaryl group Chemical group 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 444
- 108010085277 Adenosine A2A receptor Proteins 0.000 abstract description 15
- 102000007471 Adenosine A2A receptor Human genes 0.000 abstract description 14
- 230000001270 agonistic effect Effects 0.000 abstract description 8
- 230000003389 potentiating effect Effects 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 251
- 238000006243 chemical reaction Methods 0.000 description 197
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 184
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 144
- 239000000243 solution Substances 0.000 description 144
- 239000000203 mixture Substances 0.000 description 131
- 238000005160 1H NMR spectroscopy Methods 0.000 description 127
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 120
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 116
- 239000002904 solvent Substances 0.000 description 115
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 104
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 96
- 239000000843 powder Substances 0.000 description 96
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 95
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 93
- 230000002829 reductive effect Effects 0.000 description 92
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 87
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 84
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 81
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 78
- 239000011541 reaction mixture Substances 0.000 description 71
- 238000000034 method Methods 0.000 description 66
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 64
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 62
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 56
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 55
- 239000012044 organic layer Substances 0.000 description 52
- 238000010898 silica gel chromatography Methods 0.000 description 52
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 51
- 238000001816 cooling Methods 0.000 description 49
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 45
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 44
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 39
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 38
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 37
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 34
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 34
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 33
- 235000017557 sodium bicarbonate Nutrition 0.000 description 32
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 32
- 238000012360 testing method Methods 0.000 description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 31
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 30
- 239000002585 base Substances 0.000 description 30
- 238000010992 reflux Methods 0.000 description 30
- 238000003756 stirring Methods 0.000 description 29
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 28
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 28
- 239000003921 oil Substances 0.000 description 27
- 235000019198 oils Nutrition 0.000 description 27
- 238000001914 filtration Methods 0.000 description 26
- 238000010438 heat treatment Methods 0.000 description 20
- 239000003814 drug Substances 0.000 description 19
- 230000004410 intraocular pressure Effects 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- 229910000027 potassium carbonate Inorganic materials 0.000 description 18
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 17
- 239000013078 crystal Substances 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 16
- 239000002994 raw material Substances 0.000 description 16
- 229920006395 saturated elastomer Polymers 0.000 description 16
- 239000001632 sodium acetate Substances 0.000 description 16
- 235000017281 sodium acetate Nutrition 0.000 description 16
- 230000009471 action Effects 0.000 description 15
- 239000003054 catalyst Substances 0.000 description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 15
- 239000008194 pharmaceutical composition Substances 0.000 description 15
- 125000006239 protecting group Chemical group 0.000 description 15
- 235000011121 sodium hydroxide Nutrition 0.000 description 15
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 14
- FHHZOYXKOICLGH-UHFFFAOYSA-N dichloromethane;ethanol Chemical compound CCO.ClCCl FHHZOYXKOICLGH-UHFFFAOYSA-N 0.000 description 14
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 239000007858 starting material Substances 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 239000012230 colorless oil Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 13
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 13
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 12
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 12
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 12
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- 208000010412 Glaucoma Diseases 0.000 description 11
- 235000011054 acetic acid Nutrition 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 11
- 235000011118 potassium hydroxide Nutrition 0.000 description 11
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 11
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 10
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 10
- 239000012298 atmosphere Substances 0.000 description 10
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 10
- 238000007796 conventional method Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- 239000002465 adenosine A2a receptor agonist Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 9
- 230000003197 catalytic effect Effects 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- LZPVNFLWFSSMJC-UHFFFAOYSA-N dichloromethane;n,n-diethylethanamine;methanol Chemical compound OC.ClCCl.CCN(CC)CC LZPVNFLWFSSMJC-UHFFFAOYSA-N 0.000 description 9
- 239000003889 eye drop Substances 0.000 description 9
- HDJOIOGUBRECCC-UHFFFAOYSA-N n-[4-(2,2-dicyanoethenyl)phenyl]acetamide Chemical compound CC(=O)NC1=CC=C(C=C(C#N)C#N)C=C1 HDJOIOGUBRECCC-UHFFFAOYSA-N 0.000 description 9
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 9
- 238000010792 warming Methods 0.000 description 9
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 8
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000012312 sodium hydride Substances 0.000 description 8
- 229910000104 sodium hydride Inorganic materials 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 7
- JLVBSBMJQUMAMW-UHFFFAOYSA-N 6-methyl-2-pyridinemethanol Chemical compound CC1=CC=CC(CO)=N1 JLVBSBMJQUMAMW-UHFFFAOYSA-N 0.000 description 7
- LTUUGSGSUZRPRV-UHFFFAOYSA-N 6-methylpyridine-2-carboxylic acid Chemical compound CC1=CC=CC(C(O)=O)=N1 LTUUGSGSUZRPRV-UHFFFAOYSA-N 0.000 description 7
- 239000005457 ice water Substances 0.000 description 7
- 239000012442 inert solvent Substances 0.000 description 7
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 7
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 0 *c(cc1)ccc1-c1nc(S*C2=CC=CI=N2)nc(N)c1C#N Chemical compound *c(cc1)ccc1-c1nc(S*C2=CC=CI=N2)nc(N)c1C#N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 239000012300 argon atmosphere Substances 0.000 description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 6
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 239000002198 insoluble material Substances 0.000 description 6
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 6
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 230000000704 physical effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 6
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 6
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 6
- 239000005711 Benzoic acid Substances 0.000 description 5
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 150000003835 adenosine derivatives Chemical class 0.000 description 5
- 210000001742 aqueous humor Anatomy 0.000 description 5
- 235000010233 benzoic acid Nutrition 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 150000003840 hydrochlorides Chemical group 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 5
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 4
- 229940122086 Adenosine A2a receptor agonist Drugs 0.000 description 4
- 102000055025 Adenosine deaminases Human genes 0.000 description 4
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 150000001350 alkyl halides Chemical class 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 4
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000011261 inert gas Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 239000002808 molecular sieve Substances 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000002524 organometallic group Chemical group 0.000 description 4
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 4
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 4
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- XDDGKNRSCDEWBR-UHFFFAOYSA-N (6-bromopyridin-2-yl)methanol Chemical compound OCC1=CC=CC(Br)=N1 XDDGKNRSCDEWBR-UHFFFAOYSA-N 0.000 description 3
- FLWFASQXXDIDPG-SNAWJCMRSA-N (E)-3-[6-(hydroxymethyl)pyridin-2-yl]prop-2-enoic acid Chemical compound OCC1=CC=CC(\C=C\C(O)=O)=N1 FLWFASQXXDIDPG-SNAWJCMRSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 3
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- 102000009346 Adenosine receptors Human genes 0.000 description 3
- 108050000203 Adenosine receptors Proteins 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- PAOANWZGLPPROA-RQXXJAGISA-N CGS-21680 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(O)=O)=CC=3)=NC(N)=C2N=C1 PAOANWZGLPPROA-RQXXJAGISA-N 0.000 description 3
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 229910010082 LiAlH Inorganic materials 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000007239 Wittig reaction Methods 0.000 description 3
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 3
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 238000009530 blood pressure measurement Methods 0.000 description 3
- 125000006251 butylcarbonyl group Chemical group 0.000 description 3
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 3
- 125000000068 chlorophenyl group Chemical group 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 125000004675 pentylcarbonyl group Chemical group C(CCCC)C(=O)* 0.000 description 3
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 235000009518 sodium iodide Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- UWKRXXCVSYLAEG-UHFFFAOYSA-N (6-ethynylpyridin-2-yl)methanol Chemical compound OCC1=CC=CC(C#C)=N1 UWKRXXCVSYLAEG-UHFFFAOYSA-N 0.000 description 2
- PWIKWRSVKORZCB-UHFFFAOYSA-N (6-methylpyridin-2-yl)-morpholin-4-ylmethanone Chemical compound CC1=CC=CC(C(=O)N2CCOCC2)=N1 PWIKWRSVKORZCB-UHFFFAOYSA-N 0.000 description 2
- QDVBKXJMLILLLB-UHFFFAOYSA-N 1,4'-bipiperidine Chemical compound C1CCCCN1C1CCNCC1 QDVBKXJMLILLLB-UHFFFAOYSA-N 0.000 description 2
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 2
- 125000004806 1-methylethylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- JLIDVCMBCGBIEY-UHFFFAOYSA-N 1-penten-3-one Chemical compound CCC(=O)C=C JLIDVCMBCGBIEY-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- YJIWUVDKWMNHJE-UHFFFAOYSA-N 3-[6-[[tert-butyl(dimethyl)silyl]oxymethyl]pyridin-2-yl]propanoic acid Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC=CC(CCC(O)=O)=N1 YJIWUVDKWMNHJE-UHFFFAOYSA-N 0.000 description 2
- JBOFJUBAUJQTQL-UHFFFAOYSA-N 4-(6-methylpyridine-2-carbonyl)piperazine-1-carboxylic acid Chemical compound CC1=CC=CC(=N1)C(=O)N1CCN(CC1)C(=O)O JBOFJUBAUJQTQL-UHFFFAOYSA-N 0.000 description 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- USGRADVWEOYHGX-UHFFFAOYSA-N 6-(hydroxymethyl)pyridine-2-carbaldehyde Chemical compound OCC1=CC=CC(C=O)=N1 USGRADVWEOYHGX-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- QGWNDRXFNXRZMB-UUOKFMHZSA-N GDP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 238000007341 Heck reaction Methods 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 244000061458 Solanum melongena Species 0.000 description 2
- 235000002597 Solanum melongena Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- UTTMCACPUSAQDP-UHFFFAOYSA-N [6-(2-morpholin-4-ylethyl)pyridin-2-yl]methanol Chemical compound OCC1=CC=CC(CCN2CCOCC2)=N1 UTTMCACPUSAQDP-UHFFFAOYSA-N 0.000 description 2
- TYKLIICZXAJTKG-UHFFFAOYSA-N [6-(hydroxymethyl)pyridin-2-yl]-morpholin-4-ylmethanone Chemical compound OCC1=CC=CC(C(=O)N2CCOCC2)=N1 TYKLIICZXAJTKG-UHFFFAOYSA-N 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 210000000692 cap cell Anatomy 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- XHIKCWBOQBWVPU-UHFFFAOYSA-N dichloromethane;n,n-diethylethanamine;ethanol Chemical compound CCO.ClCCl.CCN(CC)CC XHIKCWBOQBWVPU-UHFFFAOYSA-N 0.000 description 2
- 108700003601 dimethylglycine Proteins 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 2
- HYYOFIQVWAGHRK-VQHVLOKHSA-N ethyl (e)-3-[6-(hydroxymethyl)pyridin-2-yl]-2-methylprop-2-enoate Chemical compound CCOC(=O)C(\C)=C\C1=CC=CC(CO)=N1 HYYOFIQVWAGHRK-VQHVLOKHSA-N 0.000 description 2
- NSRYHTRXYOVKQX-VOTSOKGWSA-N ethyl (e)-3-[6-(hydroxymethyl)pyridin-2-yl]prop-2-enoate Chemical compound CCOC(=O)\C=C\C1=CC=CC(CO)=N1 NSRYHTRXYOVKQX-VOTSOKGWSA-N 0.000 description 2
- LEFGATDLYZJIBM-UHFFFAOYSA-N ethyl 3-[6-[[tert-butyl(dimethyl)silyl]oxymethyl]pyridin-2-yl]prop-2-enoate Chemical compound CCOC(=O)C=CC1=CC=CC(CO[Si](C)(C)C(C)(C)C)=N1 LEFGATDLYZJIBM-UHFFFAOYSA-N 0.000 description 2
- ZAAFAGJHRBSLQW-UHFFFAOYSA-N ethyl 3-[6-[[tert-butyl(dimethyl)silyl]oxymethyl]pyridin-2-yl]propanoate Chemical compound CCOC(=O)CCC1=CC=CC(CO[Si](C)(C)C(C)(C)C)=N1 ZAAFAGJHRBSLQW-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 description 2
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 2
- 125000004871 hexylcarbonyl group Chemical group C(CCCCC)C(=O)* 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- HLIJMINVKPFPTC-AATRIKPKSA-N methyl (e)-3-[6-(hydroxymethyl)pyridin-2-yl]prop-2-enoate Chemical compound COC(=O)\C=C\C1=CC=CC(CO)=N1 HLIJMINVKPFPTC-AATRIKPKSA-N 0.000 description 2
- QQNPKFLLCWDGBM-UHFFFAOYSA-N methyl 3-[6-(hydroxymethyl)pyridin-2-yl]propanoate Chemical compound COC(=O)CCC1=CC=CC(CO)=N1 QQNPKFLLCWDGBM-UHFFFAOYSA-N 0.000 description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000006518 morpholino carbonyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])N(C(*)=O)C1([H])[H] 0.000 description 2
- 125000006203 morpholinoethyl group Chemical group [H]C([H])(*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 2
- PVYBFVZRZWESQN-UHFFFAOYSA-N n,n-diethyl-2-piperazin-1-ylethanamine Chemical compound CCN(CC)CCN1CCNCC1 PVYBFVZRZWESQN-UHFFFAOYSA-N 0.000 description 2
- CZFNISFYDPIDNM-UHFFFAOYSA-N n,n-dimethylformamide;oxolane Chemical compound CN(C)C=O.C1CCOC1 CZFNISFYDPIDNM-UHFFFAOYSA-N 0.000 description 2
- 229940078490 n,n-dimethylglycine Drugs 0.000 description 2
- MYBWOJIIIHZJIT-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[3-[4-[2-(diethylamino)ethyl]piperazin-1-yl]-3-oxopropyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide;hydrochloride Chemical compound Cl.C1CN(CCN(CC)CC)CCN1C(=O)CCC1=CC=CC(CSC=2N=C(C(C#N)=C(N)N=2)C=2C=CC(NC(C)=O)=CC=2)=N1 MYBWOJIIIHZJIT-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000007686 potassium Nutrition 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- KPBSJEBFALFJTO-UHFFFAOYSA-N propane-1-sulfonyl chloride Chemical compound CCCS(Cl)(=O)=O KPBSJEBFALFJTO-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000005400 pyridylcarbonyl group Chemical group N1=C(C=CC=C1)C(=O)* 0.000 description 2
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 238000003797 solvolysis reaction Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229910052717 sulfur Chemical group 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- XOUJKRYPXURYOM-UHFFFAOYSA-N tert-butyl-dimethyl-[[6-(3-morpholin-4-ylpropyl)pyridin-2-yl]methoxy]silane Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC=CC(CCCN2CCOCC2)=N1 XOUJKRYPXURYOM-UHFFFAOYSA-N 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- SQMWSBKSHWARHU-WABSSEDKSA-N (2r,4r,5r)-2-[6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound OC1[C@@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC3CCCC3)=C2N=C1 SQMWSBKSHWARHU-WABSSEDKSA-N 0.000 description 1
- ACDAPUOXXWLLSC-UHFFFAOYSA-N (3-methylpyridin-2-yl)methanol Chemical compound CC1=CC=CN=C1CO ACDAPUOXXWLLSC-UHFFFAOYSA-N 0.000 description 1
- MTYDTSHOQKECQS-UHFFFAOYSA-N (4-methylpyridin-2-yl)methanol Chemical compound CC1=CC=NC(CO)=C1 MTYDTSHOQKECQS-UHFFFAOYSA-N 0.000 description 1
- HYOBIUULDPLKIE-UHFFFAOYSA-N (5-methylpyridin-2-yl)methanol Chemical compound CC1=CC=C(CO)N=C1 HYOBIUULDPLKIE-UHFFFAOYSA-N 0.000 description 1
- GWQUDVZQAICSQN-UHFFFAOYSA-N (6-bromopyridin-2-yl)methyl acetate Chemical compound CC(=O)OCC1=CC=CC(Br)=N1 GWQUDVZQAICSQN-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- DIZQMRAFNUEVLX-VOTSOKGWSA-N (e)-1-[6-(hydroxymethyl)pyridin-2-yl]pent-1-en-3-one Chemical compound CCC(=O)\C=C\C1=CC=CC(CO)=N1 DIZQMRAFNUEVLX-VOTSOKGWSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical group C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- UXHZIFKPLFIPSX-UHFFFAOYSA-N 1-(2-pyrrolidin-1-ylethyl)piperazine Chemical compound C1CCCN1CCN1CCNCC1 UXHZIFKPLFIPSX-UHFFFAOYSA-N 0.000 description 1
- ZRNWAZPCPBGSOU-UHFFFAOYSA-N 1-(4-methylpiperazin-1-yl)pent-4-yn-1-one Chemical compound CN1CCN(C(=O)CCC#C)CC1 ZRNWAZPCPBGSOU-UHFFFAOYSA-N 0.000 description 1
- CHPLROKJXHCPLY-UHFFFAOYSA-N 1-(6-methylpyridin-2-yl)ethanol Chemical compound CC(O)C1=CC=CC(C)=N1 CHPLROKJXHCPLY-UHFFFAOYSA-N 0.000 description 1
- AJCYWKQDFBQJFR-UHFFFAOYSA-N 1-(6-methylpyridin-2-yl)pentan-1-ol Chemical compound CCCCC(O)C1=CC=CC(C)=N1 AJCYWKQDFBQJFR-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- VGEQUMWEQWWIJT-UHFFFAOYSA-N 1-[(1-methylpiperidin-4-yl)methyl]piperazine Chemical compound C1CN(C)CCC1CN1CCNCC1 VGEQUMWEQWWIJT-UHFFFAOYSA-N 0.000 description 1
- CZQCDGDBZCOODB-UHFFFAOYSA-N 1-[6-(hydroxymethyl)pyridin-2-yl]pentan-3-one Chemical compound CCC(=O)CCC1=CC=CC(CO)=N1 CZQCDGDBZCOODB-UHFFFAOYSA-N 0.000 description 1
- LLAPDLPYIYKTGQ-UHFFFAOYSA-N 1-aminoethyl Chemical group C[CH]N LLAPDLPYIYKTGQ-UHFFFAOYSA-N 0.000 description 1
- FXHRAKUEZPSMLJ-UHFFFAOYSA-N 1-methyl-1,4-diazepane Chemical compound CN1CCCNCC1 FXHRAKUEZPSMLJ-UHFFFAOYSA-N 0.000 description 1
- LSIXBBPOJBJQHN-UHFFFAOYSA-N 2,3-Dimethylbicyclo[2.2.1]hept-2-ene Chemical compound C1CC2C(C)=C(C)C1C2 LSIXBBPOJBJQHN-UHFFFAOYSA-N 0.000 description 1
- QUTSYCOAZVHGGT-UHFFFAOYSA-N 2,6-bis(bromomethyl)pyridine Chemical compound BrCC1=CC=CC(CBr)=N1 QUTSYCOAZVHGGT-UHFFFAOYSA-N 0.000 description 1
- IWQNFYRJSVJWQA-UHFFFAOYSA-N 2,6-bis(chloromethyl)pyridine Chemical compound ClCC1=CC=CC(CCl)=N1 IWQNFYRJSVJWQA-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- JPMRGPPMXHGKRO-UHFFFAOYSA-N 2-(chloromethyl)pyridine hydrochloride Chemical compound Cl.ClCC1=CC=CC=N1 JPMRGPPMXHGKRO-UHFFFAOYSA-N 0.000 description 1
- AZDXOXWFGNQSPC-UHFFFAOYSA-N 2-(piperidin-1-ylmethyl)morpholine Chemical compound C1CCCCN1CC1CNCCO1 AZDXOXWFGNQSPC-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- XNLLVFQOWJJDKV-UHFFFAOYSA-N 2-[(4-ethylpiperazin-1-yl)methyl]morpholine Chemical compound C1CN(CC)CCN1CC1OCCNC1 XNLLVFQOWJJDKV-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- HNTZKNJGAFJMHQ-UHFFFAOYSA-N 2-methylpyridine-3-carboxylic acid Chemical compound CC1=NC=CC=C1C(O)=O HNTZKNJGAFJMHQ-UHFFFAOYSA-N 0.000 description 1
- PMDHIMMPXRSDML-UHFFFAOYSA-N 2-methylpyridine-4-carboxylic acid Chemical compound CC1=CC(C(O)=O)=CC=N1 PMDHIMMPXRSDML-UHFFFAOYSA-N 0.000 description 1
- CJNRGSHEMCMUOE-UHFFFAOYSA-N 2-piperidin-1-ylethanamine Chemical compound NCCN1CCCCC1 CJNRGSHEMCMUOE-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- ALCFPNRFSFWWKR-UHFFFAOYSA-N 3-[6-[[4-(4-acetamidophenyl)-6-amino-5-cyanopyrimidin-2-yl]sulfanylmethyl]pyridin-2-yl]-2-methylpropanoic acid Chemical compound OC(=O)C(C)CC1=CC=CC(CSC=2N=C(C(C#N)=C(N)N=2)C=2C=CC(NC(C)=O)=CC=2)=N1 ALCFPNRFSFWWKR-UHFFFAOYSA-N 0.000 description 1
- MFJDLNGURXDEIN-UHFFFAOYSA-N 3-[6-[[tert-butyl(dimethyl)silyl]oxymethyl]pyridin-2-yl]-1-morpholin-4-ylpropan-1-one Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC=CC(CCC(=O)N2CCOCC2)=N1 MFJDLNGURXDEIN-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- IHBVNSPHKMCPST-UHFFFAOYSA-N 3-bromopropanoyl chloride Chemical compound ClC(=O)CCBr IHBVNSPHKMCPST-UHFFFAOYSA-N 0.000 description 1
- 229940105325 3-dimethylaminopropylamine Drugs 0.000 description 1
- LPDGWMLCUHULJF-UHFFFAOYSA-N 3-piperidin-1-ylpropanoic acid Chemical compound OC(=O)CCN1CCCCC1 LPDGWMLCUHULJF-UHFFFAOYSA-N 0.000 description 1
- SAJZEJMFAWZNCQ-UHFFFAOYSA-N 4-(2-piperazin-1-ylethyl)morpholine Chemical compound C1CNCCN1CCN1CCOCC1 SAJZEJMFAWZNCQ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- KNDCTGYZQRMVMR-UHFFFAOYSA-N 4-[3-[6-(chloromethyl)pyridin-2-yl]propyl]morpholine Chemical compound ClCC1=CC=CC(CCCN2CCOCC2)=N1 KNDCTGYZQRMVMR-UHFFFAOYSA-N 0.000 description 1
- UOJBLCQUNXHPOJ-UHFFFAOYSA-N 4-[[6-(bromomethyl)pyridin-2-yl]methyl]morpholine Chemical compound BrCC1=CC=CC(CN2CCOCC2)=N1 UOJBLCQUNXHPOJ-UHFFFAOYSA-N 0.000 description 1
- IKHZYZZSNUQGPN-UHFFFAOYSA-N 4-[[6-[[4-(4-acetamidophenyl)-6-amino-5-cyanopyrimidin-2-yl]sulfanylmethyl]pyridin-2-yl]methyl]piperazine-1-carboxylic acid Chemical compound C(C)(=O)NC1=CC=C(C=C1)C1=NC(=NC(=C1C#N)N)SCC1=CC=CC(=N1)CN1CCN(CC1)C(=O)O IKHZYZZSNUQGPN-UHFFFAOYSA-N 0.000 description 1
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
- RJWLLQWLBMJCFD-UHFFFAOYSA-N 4-methylpiperazin-1-amine Chemical compound CN1CCN(N)CC1 RJWLLQWLBMJCFD-UHFFFAOYSA-N 0.000 description 1
- ZEWPJQOFVHRHKN-UHFFFAOYSA-N 4-pyrrolidin-1-ylbutanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCCN1CCCC1 ZEWPJQOFVHRHKN-UHFFFAOYSA-N 0.000 description 1
- MYASDXFXIYRXKQ-UHFFFAOYSA-N 5-[6-(hydroxymethyl)pyridin-2-yl]-1-(4-methylpiperazin-1-yl)pent-4-yn-1-one Chemical compound C1CN(C)CCN1C(=O)CCC#CC1=CC=CC(CO)=N1 MYASDXFXIYRXKQ-UHFFFAOYSA-N 0.000 description 1
- FDIWHDGRKSMZBY-UHFFFAOYSA-N 6-[[tert-butyl(dimethyl)silyl]oxymethyl]pyridine-2-carbaldehyde Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC=CC(C=O)=N1 FDIWHDGRKSMZBY-UHFFFAOYSA-N 0.000 description 1
- RZOKQIPOABEQAM-UHFFFAOYSA-N 6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC=C(C(O)=O)C=N1 RZOKQIPOABEQAM-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 101150007969 ADORA1 gene Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 101150051188 Adora2a gene Proteins 0.000 description 1
- 101150078577 Adora2b gene Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- MYPXFDPIWHINDI-UHFFFAOYSA-N CC1=CC=C[I]=N1 Chemical compound CC1=CC=C[I]=N1 MYPXFDPIWHINDI-UHFFFAOYSA-N 0.000 description 1
- UCLFLXCJWYNSLZ-UHFFFAOYSA-N CN(CC1)CCC1N1CC(c2ccccc2)OCC1 Chemical compound CN(CC1)CCC1N1CC(c2ccccc2)OCC1 UCLFLXCJWYNSLZ-UHFFFAOYSA-N 0.000 description 1
- RFWAAXNLVJXFQD-UHFFFAOYSA-N CN(CC1)CCC1N1CCN(C)CC1 Chemical compound CN(CC1)CCC1N1CCN(C)CC1 RFWAAXNLVJXFQD-UHFFFAOYSA-N 0.000 description 1
- XTBIZRILTZVKOH-UHFFFAOYSA-N CN(CC1)CCC1N1CCN(C)CCC1 Chemical compound CN(CC1)CCC1N1CCN(C)CCC1 XTBIZRILTZVKOH-UHFFFAOYSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- OLGVTLUPYZUTKJ-UHFFFAOYSA-N CNCCCCN(CC1)CCN1C(c1ccccc1)c1ccccc1 Chemical compound CNCCCCN(CC1)CCN1C(c1ccccc1)c1ccccc1 OLGVTLUPYZUTKJ-UHFFFAOYSA-N 0.000 description 1
- WIBXUQJEDCIFGH-UHFFFAOYSA-N CNCCCN(CC1)CCN1c1ccc(C(F)(F)F)cc1 Chemical compound CNCCCN(CC1)CCN1c1ccc(C(F)(F)F)cc1 WIBXUQJEDCIFGH-UHFFFAOYSA-N 0.000 description 1
- HUGARFACUNSTSF-UHFFFAOYSA-N CNCCCN1CCN(C)CC1 Chemical compound CNCCCN1CCN(C)CC1 HUGARFACUNSTSF-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108091006101 Gi proteins Proteins 0.000 description 1
- 102000034354 Gi proteins Human genes 0.000 description 1
- 206010018307 Glaucoma and ocular hypertension Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108091006065 Gs proteins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 1
- OUXRMEUJNPVXMM-UHFFFAOYSA-N N,n-diethyl-4-piperidinamine Chemical compound CCN(CC)C1CCNCC1 OUXRMEUJNPVXMM-UHFFFAOYSA-N 0.000 description 1
- ZQFBYSFMJXKEJW-UHFFFAOYSA-N N-[2-(2,2-dicyanoethenyl)phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1C=C(C#N)C#N ZQFBYSFMJXKEJW-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010067013 Normal tension glaucoma Diseases 0.000 description 1
- IGSDGXBBKAGILS-SNAWJCMRSA-N OC(=O)\C=C\C1=CC=CC(CBr)=N1 Chemical compound OC(=O)\C=C\C1=CC=CC(CBr)=N1 IGSDGXBBKAGILS-SNAWJCMRSA-N 0.000 description 1
- CTTVRZLYCLTWSP-GQCTYLIASA-N OCC1=CC=CC(=N1)\C=C\CCC Chemical compound OCC1=CC=CC(=N1)\C=C\CCC CTTVRZLYCLTWSP-GQCTYLIASA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical class ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ZWZUFQPXYVYAFO-UHFFFAOYSA-N Tert-butyl (triphenylphosphoranylidene)acetate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OC(C)(C)C)C1=CC=CC=C1 ZWZUFQPXYVYAFO-UHFFFAOYSA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Natural products CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- RDCOUDPARZJZBP-UHFFFAOYSA-N [6-(3-morpholin-4-ylpropyl)pyridin-2-yl]methanol Chemical compound OCC1=CC=CC(CCCN2CCOCC2)=N1 RDCOUDPARZJZBP-UHFFFAOYSA-N 0.000 description 1
- LZOAOFSSIFTNCJ-UHFFFAOYSA-N [6-(chloromethyl)pyridin-2-yl]-morpholin-4-ylmethanone Chemical compound ClCC1=CC=CC(C(=O)N2CCOCC2)=N1 LZOAOFSSIFTNCJ-UHFFFAOYSA-N 0.000 description 1
- VQOITIUCXJQSGZ-UHFFFAOYSA-N [6-(hydroxymethyl)pyridin-2-yl]methyl-methylcarbamic acid Chemical compound OC(=O)N(C)CC1=CC=CC(CO)=N1 VQOITIUCXJQSGZ-UHFFFAOYSA-N 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002582 adenosine A1 receptor agonist Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical group 0.000 description 1
- 150000001348 alkyl chlorides Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004799 bromophenyl group Chemical group 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- VWLBSPOISVSPDQ-UHFFFAOYSA-N butylazanium;tetrachloride Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].CCCC[NH3+].CCCC[NH3+].CCCC[NH3+].CCCC[NH3+] VWLBSPOISVSPDQ-UHFFFAOYSA-N 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000005622 butynylene group Chemical group 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 1
- WDJQAYUPVJEQJW-UHFFFAOYSA-N chloroform;n,n-diethylethanamine;methanol Chemical compound OC.ClC(Cl)Cl.CCN(CC)CC WDJQAYUPVJEQJW-UHFFFAOYSA-N 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- SBUXRMKDJWEXRL-ROUUACIJSA-N cis-body Chemical compound O=C([C@H]1N(C2=O)[C@H](C3=C(C4=CC=CC=C4N3)C1)CC)N2C1=CC=C(F)C=C1 SBUXRMKDJWEXRL-ROUUACIJSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000005828 desilylation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- MIOUTPXNKVBIFR-UHFFFAOYSA-J dicalcium 2-hydroxyacetate Chemical compound C(CO)(=O)[O-].[Ca+2].[Ca+2].C(CO)(=O)[O-].C(CO)(=O)[O-].C(CO)(=O)[O-] MIOUTPXNKVBIFR-UHFFFAOYSA-J 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- MQYQOVYIJOLTNX-UHFFFAOYSA-N dichloromethane;n,n-dimethylformamide Chemical compound ClCCl.CN(C)C=O MQYQOVYIJOLTNX-UHFFFAOYSA-N 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 125000004188 dichlorophenyl group Chemical group 0.000 description 1
- 125000004212 difluorophenyl group Chemical group 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 125000006202 diisopropylaminoethyl group Chemical group [H]C([H])([H])C([H])(N(C([H])([H])C([H])([H])*)C([H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 1
- 229960003933 dorzolamide Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- BVSRWCMAJISCTD-UHFFFAOYSA-N ethyl 2-diethoxyphosphorylpropanoate Chemical compound CCOC(=O)C(C)P(=O)(OCC)OCC BVSRWCMAJISCTD-UHFFFAOYSA-N 0.000 description 1
- IVIKKQBZNMGVGO-UHFFFAOYSA-N ethyl 3-[6-(hydroxymethyl)pyridin-2-yl]-2-methylpropanoate Chemical compound CCOC(=O)C(C)CC1=CC=CC(CO)=N1 IVIKKQBZNMGVGO-UHFFFAOYSA-N 0.000 description 1
- NZZHLEFNGXRXDM-UHFFFAOYSA-N ethyl 3-[6-(hydroxymethyl)pyridin-2-yl]propanoate Chemical compound CCOC(=O)CCC1=CC=CC(CO)=N1 NZZHLEFNGXRXDM-UHFFFAOYSA-N 0.000 description 1
- OBPBIBMFQYAKJG-UHFFFAOYSA-N ethyl 3-[6-[[4-(4-acetamidophenyl)-6-amino-5-cyanopyrimidin-2-yl]sulfanylmethyl]pyridin-2-yl]-2-methylpropanoate Chemical compound CCOC(=O)C(C)CC1=CC=CC(CSC=2N=C(C(C#N)=C(N)N=2)C=2C=CC(NC(C)=O)=CC=2)=N1 OBPBIBMFQYAKJG-UHFFFAOYSA-N 0.000 description 1
- KAYBFLNBKIMXFA-UHFFFAOYSA-N ethyl 3-[6-[[4-(4-acetamidophenyl)-6-amino-5-cyanopyrimidin-2-yl]sulfanylmethyl]pyridin-2-yl]propanoate Chemical compound CCOC(=O)CCC1=CC=CC(CSC=2N=C(C(C#N)=C(N)N=2)C=2C=CC(NC(C)=O)=CC=2)=N1 KAYBFLNBKIMXFA-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- WICNYNXYKZNNSN-UHFFFAOYSA-N hydron;4-methylpiperazine-1-carbonyl chloride;chloride Chemical compound Cl.CN1CCN(C(Cl)=O)CC1 WICNYNXYKZNNSN-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical group 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000006303 iodophenyl group Chemical group 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 201000002978 low tension glaucoma Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- UWEFSNWAPPJALF-UHFFFAOYSA-N methyl 3-[6-[[4-(4-acetamidophenyl)-6-amino-5-cyanopyrimidin-2-yl]sulfanylmethyl]pyridin-2-yl]propanoate Chemical compound COC(=O)CCC1=CC=CC(CSC=2N=C(C(C#N)=C(N)N=2)C=2C=CC(NC(C)=O)=CC=2)=N1 UWEFSNWAPPJALF-UHFFFAOYSA-N 0.000 description 1
- MJMZBXYBWMBFNY-UHFFFAOYSA-N methyl 4-(4-nitrophenoxy)butanoate Chemical compound COC(=O)CCCOC1=CC=C([N+]([O-])=O)C=C1 MJMZBXYBWMBFNY-UHFFFAOYSA-N 0.000 description 1
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 1
- UJJREDXPLOESKR-UHFFFAOYSA-N methyl n-(4-formylphenyl)carbamate Chemical compound COC(=O)NC1=CC=C(C=O)C=C1 UJJREDXPLOESKR-UHFFFAOYSA-N 0.000 description 1
- WDGWDMJLRHXXLS-UHFFFAOYSA-N methyl n-[4-(2,2-dicyanoethenyl)phenyl]carbamate Chemical compound COC(=O)NC1=CC=C(C=C(C#N)C#N)C=C1 WDGWDMJLRHXXLS-UHFFFAOYSA-N 0.000 description 1
- NAGDRHBILKJADF-UHFFFAOYSA-N methyl n-[4-[6-amino-5-cyano-2-[(6-methylpyridin-2-yl)methylsulfanyl]pyrimidin-4-yl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OC)=CC=C1C1=NC(SCC=2N=C(C)C=CC=2)=NC(N)=C1C#N NAGDRHBILKJADF-UHFFFAOYSA-N 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- GSENCEDSCQYPIL-UHFFFAOYSA-N morpholin-4-ylmethanone Chemical compound O=[C]N1CCOCC1 GSENCEDSCQYPIL-UHFFFAOYSA-N 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- UDGSVBYJWHOHNN-UHFFFAOYSA-N n',n'-diethylethane-1,2-diamine Chemical compound CCN(CC)CCN UDGSVBYJWHOHNN-UHFFFAOYSA-N 0.000 description 1
- XRYGCVVVDCEPRL-UHFFFAOYSA-N n,1-dimethylpiperidin-4-amine Chemical compound CNC1CCN(C)CC1 XRYGCVVVDCEPRL-UHFFFAOYSA-N 0.000 description 1
- HVOYZOQVDYHUPF-UHFFFAOYSA-N n,n',n'-trimethylethane-1,2-diamine Chemical compound CNCCN(C)C HVOYZOQVDYHUPF-UHFFFAOYSA-N 0.000 description 1
- SORARJZLMNRBAQ-UHFFFAOYSA-N n,n',n'-trimethylpropane-1,3-diamine Chemical compound CNCCCN(C)C SORARJZLMNRBAQ-UHFFFAOYSA-N 0.000 description 1
- IDWCYRNCJHGJAL-UHFFFAOYSA-N n-(2-piperazin-1-ylethyl)-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C(C)C)CCN1CCNCC1 IDWCYRNCJHGJAL-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- JHEDMYVDXBVXHW-UHFFFAOYSA-N n-[4-(4-amino-5-cyano-2-sulfanyl-1,2-dihydropyrimidin-6-yl)phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=C(C#N)C(N)=NC(S)N1 JHEDMYVDXBVXHW-UHFFFAOYSA-N 0.000 description 1
- WKWPVQUZVJZOBP-UHFFFAOYSA-N n-[4-[4-amino-5-cyano-2-[[6-(morpholin-4-ylmethyl)pyridin-2-yl]methylsulfanyl]-1,2-dihydropyrimidin-6-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=C(C#N)C(N)=NC(SCC=2N=C(CN3CCOCC3)C=CC=2)N1 WKWPVQUZVJZOBP-UHFFFAOYSA-N 0.000 description 1
- XKYOXYPVDZGSDQ-UHFFFAOYSA-N n-[4-[6-amino-2-[[6-(aminomethyl)pyridin-2-yl]methylsulfanyl]-5-cyanopyrimidin-4-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=NC(SCC=2N=C(CN)C=CC=2)=NC(N)=C1C#N XKYOXYPVDZGSDQ-UHFFFAOYSA-N 0.000 description 1
- PSWNTFIMEOWDGU-UHFFFAOYSA-N n-[4-[6-amino-2-[[6-[(4-benzylpiperazin-1-yl)methyl]pyridin-2-yl]methylsulfanyl]-5-cyanopyrimidin-4-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=NC(SCC=2N=C(CN3CCN(CC=4C=CC=CC=4)CC3)C=CC=2)=NC(N)=C1C#N PSWNTFIMEOWDGU-UHFFFAOYSA-N 0.000 description 1
- QPQWJFFFOQOPDG-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[(6-methylpyridin-2-yl)methylsulfanyl]pyrimidin-4-yl]phenyl]propanamide Chemical compound C1=CC(NC(=O)CC)=CC=C1C1=NC(SCC=2N=C(C)C=CC=2)=NC(N)=C1C#N QPQWJFFFOQOPDG-UHFFFAOYSA-N 0.000 description 1
- VBKPRFRDJMCQCB-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[1-(6-methylpyridin-2-yl)ethylsulfanyl]pyrimidin-4-yl]phenyl]acetamide Chemical compound C=1C=CC(C)=NC=1C(C)SC(N=1)=NC(N)=C(C#N)C=1C1=CC=C(NC(C)=O)C=C1 VBKPRFRDJMCQCB-UHFFFAOYSA-N 0.000 description 1
- XTOUBTXSNLSPLL-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[1-(6-methylpyridin-2-yl)pentylsulfanyl]pyrimidin-4-yl]phenyl]acetamide Chemical compound C=1C=CC(C)=NC=1C(CCCC)SC(N=1)=NC(N)=C(C#N)C=1C1=CC=C(NC(C)=O)C=C1 XTOUBTXSNLSPLL-UHFFFAOYSA-N 0.000 description 1
- NUKHDOVSOJLBCH-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-(3-oxopentyl)pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide Chemical compound CCC(=O)CCC1=CC=CC(CSC=2N=C(C(C#N)=C(N)N=2)C=2C=CC(NC(C)=O)=CC=2)=N1 NUKHDOVSOJLBCH-UHFFFAOYSA-N 0.000 description 1
- VVTIAQXDCQRDRP-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-(methylaminomethyl)pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide Chemical compound CNCC1=CC=CC(CSC=2N=C(C(C#N)=C(N)N=2)C=2C=CC(NC(C)=O)=CC=2)=N1 VVTIAQXDCQRDRP-UHFFFAOYSA-N 0.000 description 1
- CUGXBJLWMINIQC-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-(morpholin-4-ylmethyl)pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=NC(SCC=2N=C(CN3CCOCC3)C=CC=2)=NC(N)=C1C#N CUGXBJLWMINIQC-UHFFFAOYSA-N 0.000 description 1
- FIOUPTYLSJQZNU-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-(piperazin-1-ylmethyl)pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide;hydrochloride Chemical compound Cl.C1=CC(NC(=O)C)=CC=C1C1=NC(SCC=2N=C(CN3CCNCC3)C=CC=2)=NC(N)=C1C#N FIOUPTYLSJQZNU-UHFFFAOYSA-N 0.000 description 1
- OTDHGPVRZXHJIH-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-(piperazine-1-carbonyl)pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide;hydrochloride Chemical compound Cl.C1=CC(NC(=O)C)=CC=C1C1=NC(SCC=2N=C(C=CC=2)C(=O)N2CCNCC2)=NC(N)=C1C#N OTDHGPVRZXHJIH-UHFFFAOYSA-N 0.000 description 1
- ITCKOFZTPOJUCW-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[(propylsulfonylamino)methyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide Chemical compound CCCS(=O)(=O)NCC1=CC=CC(CSC=2N=C(C(C#N)=C(N)N=2)C=2C=CC(NC(C)=O)=CC=2)=N1 ITCKOFZTPOJUCW-UHFFFAOYSA-N 0.000 description 1
- LDCANUNFLCOSGE-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[2-methyl-3-(4-methylpiperazin-1-yl)-3-oxopropyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide Chemical compound C1CN(C)CCN1C(=O)C(C)CC(N=1)=CC=CC=1CSC(N=1)=NC(N)=C(C#N)C=1C1=CC=C(NC(C)=O)C=C1 LDCANUNFLCOSGE-UHFFFAOYSA-N 0.000 description 1
- TYJAMHDQKAARQC-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[3-(4-methyl-1,4-diazepan-1-yl)-3-oxopropyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide;hydrochloride Chemical compound Cl.C1CN(C)CCCN1C(=O)CCC1=CC=CC(CSC=2N=C(C(C#N)=C(N)N=2)C=2C=CC(NC(C)=O)=CC=2)=N1 TYJAMHDQKAARQC-UHFFFAOYSA-N 0.000 description 1
- QRKRCTVNJUVDDM-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[3-(4-methylpiperazin-1-yl)-3-oxoprop-1-enyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide Chemical compound C1CN(C)CCN1C(=O)C=CC1=CC=CC(CSC=2N=C(C(C#N)=C(N)N=2)C=2C=CC(NC(C)=O)=CC=2)=N1 QRKRCTVNJUVDDM-UHFFFAOYSA-N 0.000 description 1
- BVBJDDCGWPATJO-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[3-(4-methylpiperazin-1-yl)-3-oxopropyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]propanamide Chemical compound C1=CC(NC(=O)CC)=CC=C1C1=NC(SCC=2N=C(CCC(=O)N3CCN(C)CC3)C=CC=2)=NC(N)=C1C#N BVBJDDCGWPATJO-UHFFFAOYSA-N 0.000 description 1
- YRJOZTPJGGHYCE-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[3-[4-(2-morpholin-4-ylethyl)piperazin-1-yl]-3-oxopropyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide;hydrochloride Chemical compound Cl.C1=CC(NC(=O)C)=CC=C1C1=NC(SCC=2N=C(CCC(=O)N3CCN(CCN4CCOCC4)CC3)C=CC=2)=NC(N)=C1C#N YRJOZTPJGGHYCE-UHFFFAOYSA-N 0.000 description 1
- BJBBVZLTCGMRGS-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[3-[4-(diethylamino)piperidin-1-yl]-3-oxopropyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide;hydrochloride Chemical compound Cl.C1CC(N(CC)CC)CCN1C(=O)CCC1=CC=CC(CSC=2N=C(C(C#N)=C(N)N=2)C=2C=CC(NC(C)=O)=CC=2)=N1 BJBBVZLTCGMRGS-UHFFFAOYSA-N 0.000 description 1
- DPCJMHVKHXNNHA-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[3-[4-[2-[di(propan-2-yl)amino]ethyl]piperazin-1-yl]-3-oxopropyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide;hydrochloride Chemical compound Cl.C1CN(CCN(C(C)C)C(C)C)CCN1C(=O)CCC1=CC=CC(CSC=2N=C(C(C#N)=C(N)N=2)C=2C=CC(NC(C)=O)=CC=2)=N1 DPCJMHVKHXNNHA-UHFFFAOYSA-N 0.000 description 1
- GVWPNOTYROGAGL-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[3-oxo-3-(4-piperidin-1-ylpiperidin-1-yl)propyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide;hydrochloride Chemical compound Cl.C1=CC(NC(=O)C)=CC=C1C1=NC(SCC=2N=C(CCC(=O)N3CCC(CC3)N3CCCCC3)C=CC=2)=NC(N)=C1C#N GVWPNOTYROGAGL-UHFFFAOYSA-N 0.000 description 1
- DOJLGAXTXLMNMM-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[3-oxo-3-[4-(2-pyrrolidin-1-ylethyl)piperazin-1-yl]propyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide;hydrochloride Chemical compound Cl.C1=CC(NC(=O)C)=CC=C1C1=NC(SCC=2N=C(CCC(=O)N3CCN(CCN4CCCC4)CC3)C=CC=2)=NC(N)=C1C#N DOJLGAXTXLMNMM-UHFFFAOYSA-N 0.000 description 1
- HDEOQUKXASZELS-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[5-(4-methylpiperazin-1-yl)-5-oxopent-1-ynyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide Chemical compound C1CN(C)CCN1C(=O)CCC#CC1=CC=CC(CSC=2N=C(C(C#N)=C(N)N=2)C=2C=CC(NC(C)=O)=CC=2)=N1 HDEOQUKXASZELS-UHFFFAOYSA-N 0.000 description 1
- ONSMYGSKGFGIHD-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[5-(4-methylpiperazin-1-yl)-5-oxopentyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide Chemical compound C1CN(C)CCN1C(=O)CCCCC1=CC=CC(CSC=2N=C(C(C#N)=C(N)N=2)C=2C=CC(NC(C)=O)=CC=2)=N1 ONSMYGSKGFGIHD-UHFFFAOYSA-N 0.000 description 1
- YNUPLEZVMOULLL-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[[4-(2-piperidin-1-ylacetyl)piperazin-1-yl]methyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide;hydrochloride Chemical compound Cl.C1=CC(NC(=O)C)=CC=C1C1=NC(SCC=2N=C(CN3CCN(CC3)C(=O)CN3CCCCC3)C=CC=2)=NC(N)=C1C#N YNUPLEZVMOULLL-UHFFFAOYSA-N 0.000 description 1
- XDXFGAJMEYYJLC-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[[4-[2-(4-methylpiperazin-1-yl)acetyl]piperazin-1-yl]methyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide;hydrochloride Chemical compound Cl.C1CN(C)CCN1CC(=O)N1CCN(CC=2N=C(CSC=3N=C(C(C#N)=C(N)N=3)C=3C=CC(NC(C)=O)=CC=3)C=CC=2)CC1 XDXFGAJMEYYJLC-UHFFFAOYSA-N 0.000 description 1
- CHYNOHGEMSYVIU-UHFFFAOYSA-N n-[4-[6-amino-5-cyano-2-[[6-[[methyl(propylsulfonyl)amino]methyl]pyridin-2-yl]methylsulfanyl]pyrimidin-4-yl]phenyl]acetamide Chemical compound CCCS(=O)(=O)N(C)CC1=CC=CC(CSC=2N=C(C(C#N)=C(N)N=2)C=2C=CC(NC(C)=O)=CC=2)=N1 CHYNOHGEMSYVIU-UHFFFAOYSA-N 0.000 description 1
- LEWWCLMQKSOSFV-UHFFFAOYSA-N n-[[6-[[4-(4-acetamidophenyl)-6-amino-5-cyanopyrimidin-2-yl]sulfanylmethyl]pyridin-2-yl]methyl]-2-(dimethylamino)acetamide Chemical compound CN(C)CC(=O)NCC1=CC=CC(CSC=2N=C(C(C#N)=C(N)N=2)C=2C=CC(NC(C)=O)=CC=2)=N1 LEWWCLMQKSOSFV-UHFFFAOYSA-N 0.000 description 1
- XBIBMTAGLXILIB-UHFFFAOYSA-N n-[[6-[[4-(4-acetamidophenyl)-6-amino-5-cyanopyrimidin-2-yl]sulfanylmethyl]pyridin-2-yl]methyl]-4-methylpiperazine-1-carboxamide Chemical compound C1CN(C)CCN1C(=O)NCC1=CC=CC(CSC=2N=C(C(C#N)=C(N)N=2)C=2C=CC(NC(C)=O)=CC=2)=N1 XBIBMTAGLXILIB-UHFFFAOYSA-N 0.000 description 1
- FNOOXERYDNCFMQ-UHFFFAOYSA-N n-[[6-[[4-(4-acetamidophenyl)-6-amino-5-cyanopyrimidin-2-yl]sulfanylmethyl]pyridin-2-yl]methyl]-4-pyrrolidin-1-ylbutanamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=NC(SCC=2N=C(CNC(=O)CCCN3CCCC3)C=CC=2)=NC(N)=C1C#N FNOOXERYDNCFMQ-UHFFFAOYSA-N 0.000 description 1
- BSJIWZIMZZBNAY-UHFFFAOYSA-N n-[[6-[[4-(4-acetamidophenyl)-6-amino-5-cyanopyrimidin-2-yl]sulfanylmethyl]pyridin-2-yl]methyl]-n-methyl-4-pyrrolidin-1-ylbutanamide;hydrochloride Chemical compound Cl.C1CCCN1CCCC(=O)N(C)CC(N=1)=CC=CC=1CSC(N=1)=NC(N)=C(C#N)C=1C1=CC=C(NC(C)=O)C=C1 BSJIWZIMZZBNAY-UHFFFAOYSA-N 0.000 description 1
- LCMCAQXDHPWNSF-UHFFFAOYSA-N n-[[6-[[4-(4-acetamidophenyl)-6-amino-5-cyanopyrimidin-2-yl]sulfanylmethyl]pyridin-2-yl]methyl]prop-2-enamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=NC(SCC=2N=C(CNC(=O)C=C)C=CC=2)=NC(N)=C1C#N LCMCAQXDHPWNSF-UHFFFAOYSA-N 0.000 description 1
- SQMWSBKSHWARHU-SDBHATRESA-N n6-cyclopentyladenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC3CCCC3)=C2N=C1 SQMWSBKSHWARHU-SDBHATRESA-N 0.000 description 1
- 125000005185 naphthylcarbonyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- PRGUDWLMFLCODA-UHFFFAOYSA-N oxybuprocaine hydrochloride Chemical compound [Cl-].CCCCOC1=CC(C(=O)OCC[NH+](CC)CC)=CC=C1N PRGUDWLMFLCODA-UHFFFAOYSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000003008 phosphonic acid esters Chemical class 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- PRAYXGYYVXRDDW-UHFFFAOYSA-N piperidin-2-ylmethanol Chemical compound OCC1CCCCN1 PRAYXGYYVXRDDW-UHFFFAOYSA-N 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000004673 propylcarbonyl group Chemical group 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000005412 pyrazyl group Chemical group 0.000 description 1
- GHFGOVUYCKZOJH-UHFFFAOYSA-N pyridine-2,3-dicarbonitrile Chemical class N#CC1=CC=CN=C1C#N GHFGOVUYCKZOJH-UHFFFAOYSA-N 0.000 description 1
- IIHQNAXFIODVDU-UHFFFAOYSA-N pyrimidine-2-carbonitrile Chemical class N#CC1=NC=CC=N1 IIHQNAXFIODVDU-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 1
- 229950008081 unoprostone isopropyl Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
R1は水素原子、低級アルキルカルボニル基、低級アルケニルカルボニル基、フェニルカルボニル基または低級アルコキシカルボニル基を示す。
R2は低級アルキレン基を示す。
R3は(1)水素原子、(2)低級アルキル基または下記基(3)〜基(12)のいずれかを示す。
で表される4-アミノ-5-シアノピリミジン誘導体またはその製剤学的に許容される塩。
1) N-{4-[6-アミノ-5-シアノ-2-(ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド、
2) N-{4-[6-アミノ-5-シアノ-2-(6-メチルピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド、
3) N-{4-[6-アミノ-5-シアノ-2-(6-{4-[2-(4-メチルピペラジン-1-イル)アセチル]ピペラジン-1-イルメチル}ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド、
4) N-[4-(6-アミノ-5-シアノ-2-{6-[3-(4-メチルピペラジン-1-イル)-3-オキソプロピル]ピリジン-2-イルメチルスルファニル}ピリミジン-4-イル)フェニル]アセトアミド、
5) 3-{6-[4-(4-アセチルアミノフェニル)-6-アミノ-5-シアノピリミジン-2-イルスルファニルメチル]ピリジン-2-イル}-N-(2-ジメチルアミノエチル)プロピオンアミド、
6) 3-{6-[4-(4-アセチルアミノフェニル)-6-アミノ-5-シアノピリミジン-2-イルスルファニルメチル]ピリジン-2-イル}-N-(2-ジメチルアミノエチル)-N-メチルプロピオンアミド、
7) 3-{6-[4-(4-アセチルアミノフェニル)-6-アミノ-5-シアノピリミジン-2-イルスルファニルメチル]ピリジン-2-イル}-N-(2-ジメチルアミノプロピル)-N-メチルプロピオンアミド、
8) 3-{6-[4-(4-アセチルアミノフェニル)-6-アミノ-5-シアノピリミジン-2-イルスルファニルメチル]ピリジン-2-イル}-N-(2-メチルピペリジン-1-イルエチル)プロピオンアミド、
9) 3-{6-[4-(4-アセチルアミノフェニル)-6-アミノ-5-シアノピリミジン-2-イルスルファニルメチル]ピリジン-2-イル}-N-(2-ジエチルアミノエチル)プロピオンアミド、
10) 3-{6-[4-(4-アセチルアミノフェニル)-6-アミノ-5-シアノピリミジン-2-イルスルファニルメチル]ピリジン-2-イル}-N-メチル-N-(1-メチルピペリジン-4-イル)プロピオンアミド、
11) N-(4-{6-アミノ-2-[6-(3-[1,4’]ビピペリジニル-1’-イル-3-オキソプロピル)ピリジン-2-イルメチルスルファニル]-5-シアノピリミジン-4-イル}フェニル)アセトアミド、
12) N-[4-(6-アミノ-5-シアノ-2-{6-[3-オキソ-3-(2-ピペリジン-1-イルメチルモルホリン-4-イル)プロピル]ピリジン-2-イルメチルスルファニル}ピリミジン-4-イル)フェニル]アセトアミド、
13) N-{4-[6-アミノ-5-シアノ-2-(6-{3-[2-(4-エチルピペラジン-1-イルメチル)モルホリン-4-イル]-3-オキソプロピル}ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド、
14) N-{4-[6-アミノ-5-シアノ-2-(6-{3-[4-(2-ジエチルアミノエチル)ピペラジン-1-イル]-3-オキソプロピル}ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド、
15) N-{4-[6-アミノ-5-シアノ-2-(6-{3-[4-(2-ジイソプロピルアミノエチル)ピペラジン-1-イル]-3-オキソプロピル}ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド、
16) N-{4-[6-アミノ-5-シアノ-2-(6-{3-オキソ-3-[4-(2-ピロリジン-1-イルエチル)ピペラジン-1-イル]プロピル}ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド、
17) N-{4-[6-アミノ-5-シアノ-2-(6-{3-[4-(2-モルホリン-4-イルエチル)ピペラジン-1-イル]-3-オキソプロピル}ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド、
18) N-{4-[6-アミノ-5-シアノ-2-(6-{3-[4-(2-ジエチルアミノエチル)ピペラジン-1-イル]-3-オキソプロピル}ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド、
19) N-[4-(6-アミノ-5-シアノ-2-{6-[3-(4-メチル-[1,4]ジアゼパン-1-イル)-3-オキソプロピル]ピリジン-2-イルメチルスルファニル}ピリミジン-4-イル)フェニル]アセトアミド。
本明細書において炭素を含む各基につき用いられる「低級アルキル基」とは、炭素数1乃至6の、即ちC1-6の直鎖または分枝のアルキル基を意味する。
ル、ピペリジノピペリジノメチルカルボニル、ピペリジルピペリジノエチルカルボニル、モルホリノピペリジノエチルカルボニル、ピペラジノピペリジノプロピルカルボニル基などが例示できる。該基としては、好ましくは、
1) N-{4-[6-アミノ-5-シアノ-2-(ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド
2) N-{4-[6-アミノ-5-シアノ-2-(6-メチルピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド
3) N-{4-[6-アミノ-5-シアノ-2-(6-{4-[2-(4-メチルピペラジン-1-イル)アセチル]ピペラジン-1-イルメチル}ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド
4) N-[4-(6-アミノ-5-シアノ-2-{6-[3-(4-メチルピペラジン-1-イル)-3-オキソプロピル]ピリジン-2-イルメチルスルファニル}ピリミジン-4-イル)フェニル]アセトアミド
5) 3-{6-[4-(4-アセチルアミノフェニル)-6-アミノ-5-シアノピリミジン-2-イルスルファニルメチル]ピリジン-2-イル}-N-(2-ジメチルアミノエチル)プロピオンアミド
6) 3-{6-[4-(4-アセチルアミノフェニル)-6-アミノ-5-シアノピリミジン-2-イルスルファニルメチル]ピリジン-2-イル}-N-(2-ジメチルアミノエチル)-N-メチルプロピオンアミド
7) 3-{6-[4-(4-アセチルアミノフェニル)-6-アミノ-5-シアノピリミジン-2-イルスルファニルメチル]ピリジン-2-イル}-N-(2-ジメチルアミノプロピル)-N-メチルプロピオンアミド
8) 3-{6-[4-(4-アセチルアミノフェニル)-6-アミノ-5-シアノピリミジン-2-イルスルファニルメチル]ピリジン-2-イル}-N-(2-メチルピペリジン-1-イルエチル)プロピオンアミド
9) 3-{6-[4-(4-アセチルアミノフェニル)-6-アミノ-5-シアノピリミジン-2-イルスルファニルメチル]ピリジン-2-イル}-N-(2-ジエチルアミノエチル)プロピオンアミド
10) 3-{6-[4-(4-アセチルアミノフェニル)-6-アミノ-5-シアノピリミジン-2-イルスルファニルメチル]ピリジン-2-イル}-N-メチル-N-(1-メチルピペリジン-4-イル)プロピオンアミド
11) N-(4-{6-アミノ-2-[6-(3-[1,4’]ビピペリジニル-1’-イル-3-オキソプロピル)ピリジン-2-イルメチルスルファニル]-5-シアノピリミジン-4-イル}フェニル)アセトアミド
12) N-[4-(6-アミノ-5-シアノ-2-{6-[3-オキソ-3-(2-ピペリジン-1-イルメチルモルホリン-4-イル)プロピル]ピリジン-2-イルメチルスルファニル}ピリミジン-4-イル)フェニル]アセトアミド
13) N-{4-[6-アミノ-5-シアノ-2-(6-{3-[2-(4-エチルピペラジン-1-イルメチル)モルホリン-4-イル]-3-オキソプロピル}ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド
14) N-{4-[6-アミノ-5-シアノ-2-(6-{3-[4-(2-ジエチルアミノエチル)ピペラジン-1-イル]-3-オキソプロピル}ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド
15) N-{4-[6-アミノ-5-シアノ-2-(6-{3-[4-(2-ジイソプロピルアミノエチル)ピペラジン-1-イル]-3-オキソプロピル}ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド
16) N-{4-[6-アミノ-5-シアノ-2-(6-{3-オキソ-3-[4-(2-ピロリジン-1-イルエチル)ピペラジン-1-イル]プロピル}ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド
17) N-{4-[6-アミノ-5-シアノ-2-(6-{3-[4-(2-モルホリン-4-イルエチル)ピペラジン-1-イル]-3-オキソプロピル}ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド
18) N-{4-[6-アミノ-5-シアノ-2-(6-{3-[4-(2-ジエチルアミノエチル)ピペラジン-1-イル]-3-オキソプロピル}ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド
19) N-[4-(6-アミノ-5-シアノ-2-{6-[3-(4-メチル-[1,4]ジアゼパン-1-イル)-3-オキソプロピル]ピリジン-2-イルメチルスルファニル}ピリミジン-4-イル)フェニル]アセトアミド。
以下、本発明化合物(その製剤学的に許容される塩を含む。以下、特筆しない限りこれらを「本発明化合物」)という)の製造法につき詳述する。
本発明化合物(1)は、アルデヒド体(化合物(2a))からジシアノエチレン体(化合物(2b))および2-メルカプトピリミジン体(化合物(2c))または2-メルカプトジヒドロピリミジン体(化合物(2d))を経て製造できる。
反応工程式-2に示す方法によれば、本発明化合物(1)は、チオウレア(12)と化合物(13)との反応によって製造される化合物(3a)と化合物(2b)との反応によって、化合物(2e)を経て製造することができる。即ち、本発明化合物(1)は、上記反応によって化合物(2e)(ジヒドロピリミジン体)を経て、該化合物(2e)との混合物として得られる。
反応工程式-3に示す方法によれば、チオウレア(12)と化合物(13)との反応により得られる化合物(3a)を単離し若しくは単離することなく、該化合物に化合物(2a)およびマロノニトリル(11)を同時に反応させることによって、本発明化合物(1)またはそのジヒドロ体(2e)或いはこれらの混合物を得ることができる。
前記反応工程式-1〜反応工程式-3において出発原料として利用する化合物(13)は、その有するR2基およびR3基の種類に応じて新規化合物を含んでいる。これらの化合物は、例えば下記反応工程式-4〜反応工程式-9に記載の各方法に従って製造することができる。
反応工程式-4によれば、R2がメチレン基であり、R3が基(3)、基(6)および基(8)である本発明化合物の出発物質(化合物(4b))を、公知の化合物(4a)と化合物(15)との反応により製造することができる。
反応工程式-5によれば、R2がメチレン基であり、R3が基(4)、基(5)または基(7)である本発明化合物の出発物質(化合物(5e))を製造できる。この方法に示す各反応は次のようにして実施できる。即ち、6-メチル-2-ピコリン酸(16) (または6-メチル-3-ピコリン酸, 6-メチル-4-ピコリン酸, 6-メチル-5-ピコリン酸)から常法に従って得られる化合物(5a)に、ジエチルエーテル、THF、ジオキサン、アセトニトリル、塩化メチレン、ジクロロエタン、クロロホルムなどの反応に不活性な溶媒中で、m-クロロ過安息香酸(m-CPBA)、過酸化水素水などの酸化剤を化合物(5a)に対して等モル量〜過剰モル量反応させて、化合物(5b)を得る。反応温度としては氷冷温度乃至は溶媒の加熱還流温度を採用できる。特にこの反応は、過剰量のm-CPBAなどの酸化剤を用いて、クロロホルム中、室温下で実施されるのが望ましい。
上記において、R13で示される保護基には、例えばアセチル基、メトキシメチル基、テトラヒドロピラニル基などのアルコール性水酸基の保護に通常用いられる保護基が含まれる。
反応工程式-7に示す方法によれば、R2がメチレン基であり、R3が基(9)であり、Z3が(c2)低級アルコキシ基である本発明化合物の出発原料(化合物(7d))、およびR2がメチレン基であり、R3が基(10)であり、Z3が(c2)低級アルコキシ基である本発明化合物の出発原料(化合物(7e))を合成することができる。
前記反応工程式-7に示した化合物(7b)は、また、上記反応工程式-8に示すように、公知の化合物(8a)を出発原料として用いて、Wittig反応(A.Maercher,OR,14,270(1965) B.E.Maryanoff et al.,CRV,89,863(1989))またはWittig-Horner反応(Wittig反応においてホスホニウム塩に換えて対応するホスホン酸エステルを用いる反応)に従っても製造することもできる。
R2がメチレン基であり且つR3が(2)低級アルキル基である本発明化合物の出発原料化合物(化合物(9b))、R2がメチレン基であり且つR3が基(9)(但しZ3は低級アルコキシ(c2)である)の本発明化合物の出発原料化合物(化合物(9a))、およびR2がメチレン基であり且つR3が基(11)(但しZ3はその4位に低級アルキル基を有する(c5)-である)の本発明化合物の出発原料化合物(化合物(9c))は、反応工程式-9に示す方法に従って製造することができる。
反応工程式-10に示すように、一般式(1)中、R1が水素原子である本発明化合物(化合物1B)は、R1がアセチル基などのアルキルカルボニル基である本発明化合物(1A)を、水、DMF、DMSO、ジエチルジエチルエーテル、THF、ジオキサン、アセトン、MEK、メタノール、エタノール、アセトニトリル、塩化メチレン、ジクロロエタン、クロロホルムなどの反応に不活性な溶媒中で、化合物(1A)に対して等モル量〜過剰モル量の炭酸カリウム、炭酸水素ナトリウム、酢酸ナトリウム、水酸化ナトリウム、水酸化カリウム、ナトリウムメトキシド、ナトリウムエトキシドなどの塩基若しくは塩酸、硫酸、酢酸、クエン酸などの酸を作用させることで加水分解して得ることができる。該加水分解反応は、室温乃至加温下で実施できる。特に、該加水分解反応は、エタノールおよび水の混合液中、塩酸水溶液を加えて80℃で加熱攪拌することにより行われるのが好ましい。
反応工程式-11に示すように、一般式(1)中、R3が基(6)であり且つZ1が(32)水素原子である本発明化合物(1E)は、一般式(1)中、R3が基(6)であり且つZ1が(a12)または(a28)に記載の各基、即ち脱離可能な基である本発明化合物(1D)から該脱離基可能な基を脱離反応させることにより合成できる。より詳しくは、本発明化合物(1D)に、水、DMF、DMSO、ジエチルエーテル、THF、ジオキサン、アセトン、MEK、メタノール、エタノール、アセトニトリル、塩化メチレン、ジクロロエタン、クロロホルムなどの反応に不活性な溶媒中または無溶媒で、該化合物(1D)に対して等モル量〜過剰モル量の炭酸カリウム、炭酸水素ナトリウム、酢酸ナトリウム、水酸化ナトリウム、水酸化カリウム、ナトリウムメトキシド、ナトリウムエトキシドなどの塩基若しくは塩酸、硫酸などの鉱酸または酢酸、トリフルオロ酢酸、クエン酸などの有機酸を作用させ、加水分解させることで得ることができる。該加水分解反応は、氷冷温度、室温および加温のいずれの温度条件下でも実施できる。特に好ましくは、Z1aがBOC基(t-butoxycarbonyl基) である本発明化合物に対し、無溶媒で過剰量のトリフルオロ酢酸を用いて、室温下に攪拌する方法を挙げることができる。
反応工程式-12に示すように、R3が基(9)でありZ3が(c1)水酸基である本発明化合物(1H)は、R3が基(9)でありZ3が低級アルコキシ基である本発明化合物(1G)から合成できる。この反応は、例えば本発明化合物(1G)に、水、DMF、DMSO、ジエチルエーテル、THF、ジオキサン、アセトン、MEK、メタノール、エタノール、アセトニトリル、塩化メチレン、ジクロロエタン、クロロホルムなどの反応に不活性な溶媒中または無溶媒で、該化合物に対して等モル量〜過剰モル量の炭酸カリウム、炭酸水素ナトリウム、酢酸ナトリウム、水酸化ナトリウム、水酸化カリウム、ナトリウムメトキシド、ナトリウムエトキシドなどの塩基若しくは塩酸、硫酸などの鉱酸または酢酸、トリフルオロ酢酸、クエン酸などの有機酸を作用させて加水分解することにより実施できる。該加水分解反応は、氷冷温度、室温または加温下で進行する。特に、Z3aがtert-ブトキシ基である本発明化合物に対して無溶媒で、過剰量のトリフルオロ酢酸を用いて、室温下で攪拌する方法の採用が好ましい。
本発明化合物およびその塩は、アデノシンA2a受容体を作動させる活性を有しており、アデノシンA2a受容体作動薬として、ヒトを含むほ乳類に対して、医薬品分野で有用である。従って、本発明はこのようなアデノシンA2a受容体作動薬などの医薬用途に適した医薬組成物をも提供する。以下、この医薬組成物を「本発明医薬組成物」ということがある。
内部標準物質:TMS
s : singlet, d : doublet, t : triplet, q : quartet, quint : quintet, sext : sextet
また、各例に用いる略号は次のことを示す。
WSC:1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩
LiAlH4 :水素化リチウムアルミニウム
THF:テトラヒドロフラン
TBAF:テトラブチルアンモニウムフルオリド
TBAF/THF溶液:テトラブチルアンモニウムフルオリドとテトラヒドロフランとの混液
DMF:N,N-ジメチルホルムアミド
HOBt:1-ヒドロキシベンゾトリアゾール
m-CPBA:m-クロロ過安息香酸
EtOH:エタノール
NBS:N-ブロモスクシンイミド
DDQ:2,3-ジクロロ-5,6-ジシアノ-p-ベンゾキノン
DMSO:ジメチルスルホキシド
BOPおよびBOP試薬:ヘキサフルオロりん酸ベンゾトリアゾール-1-イルオキシトリス(ジメチルアミノ)ホスホニウム
TFA:トリフルオロ酢酸。
(4-ホルミルフェニル)カルバミン酸メチルエステル560mgおよびマロノニトリル206mgをエタノール10mLに溶解し、得られた溶液にピペリジン1滴を加え、混合物を室温で3時間攪拌した。反応液にIPE10mLを加え、析出した結晶を濾取して、441mgの[4-(2,2-ジシアノビニル)フェニル]カルバミン酸メチルエステルを得た。
黄色粉末
1H-NMR (CDCl3) δ: 7.90 (2H, d, J = 8.7 Hz), 7.65 (1H, s), 7.56 (2H, d, J = 8.7 Hz), 6.92 (1H, br s), 3.83 (3H, s)。
無水エタノール20mLに金属ナトリウム250mgを少量ずつ加えて完全に溶解させた後、得られた液中にチオウレア760mgを加え、混合物を室温で1時間撹拌した。反応液にN-[-(2,2-ジシアノビニル)フェニル]アセトアミド2.11gを加え、3時間加熱還流した。その後、反応液から溶媒を減圧留去し、残留物を水30mLに溶解し、更にこの溶液に酢酸を少量ずつ加えて液性を酸性とし、次いで酢酸エチル30mLを加えて終夜撹拌した。析出した不溶物を濾取して、1.2gのN-[4-(6-アミノ-5-シアノ-2-メルカプト-2,3-ジヒドロピリミジン-4-イル)フェニル]アセトアミドを得た。
白色粉末
1H-NMR (DMSO-d6) δ: 9.98 (1H, s), 9.65 (1H, br s), 7.56 (2H, d, J= 8.7 Hz), 7.14 (2H, d, J= 8.7 Hz), 6.16 (2H, s), 4.92(1H, s), 2.08 (3H, s)。
2,6-ビス(ブロモメチル)ピリジン265mgをエタノール2mLに懸濁させ、得られた懸濁液に氷冷下にモルホリン87mgを加え、混合液を室温で終夜攪拌した。反応混合物を減圧下に濃縮し、濃縮物をシリカゲルカラムクロマトグラフィー(塩化メチレン−エタノール−トリエチルアミン=400:20:1(v/v、以下同じ))で精製して、90mgの4-(6-ブロモメチルピリジン-2-イルメチル)モルホリンを得た。
白色粉末
1H-NMR (CDCl3) δ: 10.0 (1H, s), 7.54-7.48 (2H, m), 7.42 (1H, s), 7.24 (1H, s), 4.08 (2H, t, J = 6.0 Hz), 3.56 (2H, t, J = 4.5 Hz), 2.49 (2H, t, J = 7.2 Hz), 2.42-2.34 (4H, m), 1.89 (2H, quint., J = 6.6 Hz)。
(1) 酢酸6-ブロモピリジン-2-イルメチルエステル2.3g、トリメチルシリルアセチレン1.18g、ビス(トリフェニルホスフィン)塩化パラジウム(II) 210mg、よう化銅(I)114mgおよびトリエチルアミン12mLをナス型フラスコに入れ、アルゴン雰囲気下に5時間加熱還流した。反応混合物を放冷後、減圧乾固し、水を加え、酢酸エチルで抽出した。有機層を減圧濃縮し、濃縮物にメタノール7mLおよび1N水酸化カリウム水溶液30mLを加えて1時間撹拌した。反応液を1N塩酸にて酸性にし、減圧濃縮した。濃縮液を炭酸カリウムにて塩基性にし、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸マグネシウムで乾燥後、溶媒を減圧留去した。かくして得られた生成物を、シリカゲルカラムクロマトグラフィー(ヘキサン−酢酸エチル=4:1)で精製して、212mgの(6-エチニルピリジン-2-イル)メタノールを得た。
白色粉末
1H-NMR (CDCl3) δ: 7.67 (1H, t, J = 7.8 Hz), 7.40 (1H, d, J = 7.8 Hz), 7.28 (1H, d, J = 7.8 Hz), 4.76 (2H, d, J = 5.1 Hz), 3.38 (1H, t, J = 5.1 Hz), 3.18 (1H, s)。
黄色油状物
1H-NMR (CDCl3) δ: 7.60 (1H, t, J = 7.8 Hz), 7.08 (1H, d, J = 7.8 Hz), 7.03 (1H, d, J = 7.8 Hz), 4.72 (2H, s), 3.73 (4H, t, J = 4.5 Hz), 3.00 (2H, dd, J = 10, 8.7 Hz), 2.77 (2H, dd, J = 10, 8.7 Hz), 2.53 (4H, t, J = 4.5 Hz)。
黄色油状物
1H-NMR (CDCl3) δ: 7.62 (1H, t, J = 7.8 Hz), 7.30 (1H, d, J = 7.8 Hz), 7.12 (1H, d, J = 7.8 Hz), 4.64 (2H, s), 3.72 (4H, t, J = 4.8 Hz), 2.98 (2H, dd, J = 10, 8.7 Hz), 2.74 (2H, dd, J = 10, 8.7 Hz), 2.53 (4H, t, J = 4.8 Hz)。
(1) 6-(t-ブチルジメチルシラニルオキシメチル)ピリジン-2-カルボキシアルデヒド4.29gをDMF50mLに溶解し、溶解液に(カルボエトキシメチレン)トリフェニルホスホラン7.14gを加え、室温で1時間攪拌した。反応液を氷水にあけ、酢酸エチル抽出した。有機層を水洗し、無水硫酸マグネシウムで乾燥し、減圧乾固した。残渣にヘキサン−酢酸エチル (5:1)混液100mLを加え、不溶物を濾去し、濾液を減圧濃縮した。残渣をシリカゲルカラムクロマトグラフィー(ヘキサン−酢酸エチル=10:1)で精製して、5.45gの3-[6-(t-ブチルジメチルシラニルオキシメチル)ピリジン-2-イル]アクリル酸エチルエステルを得た。
淡黄色油状物
1H-NMR (CDCl3) δ: 7.72 (1H, t, J = 7.5 Hz), 7.66 (1H, d, J = 15.6 Hz), 7.49 (1H, d, J = 7.5 Hz), 7.29 (1H, d, J = 7.5 Hz), 6.88 (1H, d, J = 15.6 Hz), 4.83 (2H, s), 4.27 (2H, q, J = 7.2 Hz), 1.33 (3H, t, J = 7.2 Hz), 0.97 (9H, s), 0.13 (6H, s)。
淡黄色油状物
1H-NMR (CDCl3) δ: 7.60 (1H, t, J = 7.5 Hz), 7.33 (1H, d, J = 7.5 Hz), 7.03 (1H, d, J = 7.5 Hz), 4.79 (2H, s), 4.12 (2H, q, J = 7.2 Hz), 3.07 (2H, t, J = 7.5 Hz), 2.75 (2H, t, J = 7.5 Hz), 1.23 (3H, t, J = 7.2 Hz), 0.96 (9H, s), 0.11 (6H, s)。
無色粉末
1H-NMR (CDCl3) δ: 7.77 (1H, t, J = 7.5 Hz), 7.47 (1H, d, J = 7.5 Hz), 7.13 (1H, d, J = 7.5 Hz), 4.84 (2H, s), 3.15 (2H, t, J = 6.0 Hz), 2.82 (2H, t, J = 6.0 Hz), 0.96 (9H, s), 0.14 (6H, s)。
黄色油状物
1H-NMR (CDCl3) δ: 7.60 (1H, t, J = 7.5 Hz), 7.33 (1H, d, J = 7.5 Hz), 7.08 (1H, d, J = 7.5 Hz), 4.79 (2H, s), 3.62-3.43 (8H, m), 3.11 (2H, t, J = 7.5 Hz), 2.77 (2H, t, J = 7.5 Hz), 0.96(9H, s), 0.12(6H, s)。
黄色粉末
1H-NMR (CDCl3) δ: 7.57 (1H, t, J = 7.8 Hz), 7.05(1H, d, J = 7.8 Hz), 7.02 (1H, d, J= 7.8 Hz), 4.65 (2H, s), 3.72 (4H, t, J = 4.8 Hz), 2.83 (2H, t, J = 7.8 Hz), 2.47-2.23 (6H, m), 1.96 (2H, quint., J= 7.8 Hz)。
2,6-ビス(クロロメチル)ピリジン352mgをエタノール4mLに懸濁させ、この懸濁液に氷冷下にN-(t-ブトキシカルボニル)ピペラジン372mgを加え、室温で終夜攪拌した。反応混合物を減圧濃縮し、残留物に水を加え、クロロホルム抽出した。有機層を飽和食塩水で洗浄し、無水硫酸マグネシウムで乾燥後、溶媒を留去した。残留物をシリカゲルカラムクロマトグラフィー(塩化メチレン−エタノール=30:1)で精製して、250mgの4-(6-クロロメチルピリジン-2-イルメチル)ピペラジン-1-カルボン酸 t-ブチルエステルを得た。
無色油状物
1H-NMR (CDCl3) δ: 7.69 (1H, t, J = 7.8 Hz), 7.37 (1H, dd, J = 7.8, 2.1 Hz), 4.66 (2H, s), 3.67 (2H, s), 3.45 (4H, t, J = 5.1 Hz), 2.45 (4H, t, J = 5.1 Hz), 1.48 (9H, s)。
(1) 6-メチルピコリン酸1.37gおよびモルホリン870mgをDMF30mLに溶解し、溶解液中に氷冷下に攪拌しながらHOBt1.6gを加えた。混合物を同温で15分間攪拌後、更にWSC2.3gを加え、室温で終夜攪拌した。反応混合物を減圧濃縮し、残留物に水を加え、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸マグネシウムで乾燥後、溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー(塩化メチレン−メタノール−トリエチルアミン=900:30:1)で精製して、1.71 gの(6-メチルピリジン-2-イル)モルホリン-4-イルメタノンを得た。
無色油状物
1H-NMR (CDCl3) δ: 7.67 (1H, t, J = 7.8 Hz), 7.41 (1H, d, J = 7.8 Hz), 7.20 (1H, d, J = 7.8 Hz), 3.80 (4H, br s), 3.67-3.58 (4H, m), 2.57 (3H, s)。
白色粉末
1H-NMR (CDCl3) δ: 7.31-7.18 (3H, m), 3.94-3.64 (6H, m), 3.30-3.20 (1H, m), 3.18-3.12 (1H, m), 2.52 (3H, s)。
黄色油状物
1H-NMR (CDCl3) δ: 7.82 (1H, t, J = 7.8 Hz), 7.61 (1H, d, J = 7.8 Hz), 7.42 (1H, d, J = 7.8 Hz), 5.22 (2H, s), 3.82 (4H, br s), 3.67-3.65 (4H, m), 2.17 (3H, s)。
白色粉末
1H-NMR (CDCl3) δ: 7.81 (1H, t, J = 7.8 Hz), 7.57 (1H, d, J = 7.8 Hz), 7.33 (1H, d, J = 7.8 Hz), 4.79 (2H, s), 3.82 (4H, br s), 3.68 (2H, t, J = 4.8 Hz), 3.58 (2H, t, J = 4.8 Hz)。
黄色油状物
1H-NMR (CDCl3) δ: 7.84 (1H, t, J = 7.8 Hz), 7.70 (1H, d, J = 7.8 Hz), 7.52 (1H, d, J = 7.8 Hz), 4.65 (2H, s), 3.82 (4H, br s), 3.69-3.65 (4H, m)。
(1) 6-メチルピリジン-2-カルボン酸 t-ブチルエステル3.03gをクロロホルム30mLに溶解し、得られた液にm-CPBA3.96gのクロロホルム45mL溶液を滴下し、混合物を室温で終夜攪拌した。反応液を分液ロートに移し、10%Na2SO3水溶液35mLを加えて分液した。有機層を飽和炭酸水素ナトリウム水溶液および飽和食塩水で洗浄した後、無水硫酸マグネシウムで乾燥し、溶媒を留去した。残渣をシリカゲルカラムクロマトグラフィー(塩化メチレン−エタノール=30:1)で精製して、3.28 gの6-メチル-1-オキシピリジン-2-カルボン酸 t-ブチルエステルを得た。
無色油状物
1H-NMR (CDCl3) δ: 7.29-7.13 (3H, m), 2.66 (3H, s), 1.63 (9H, s).
(2) 6-メチル-1-オキシピリジン-2-カルボン酸 t-ブチルエステル3.28gに無水酢酸1.5mLを加え、混合物を100℃で1時間攪拌した。反応混合物に飽和炭酸水素ナトリウム水溶液を加えて中和し、クロロホルム抽出した。有機層を飽和食塩水で洗浄し、無水硫酸マグネシウムで乾燥後、溶媒を留去した。残渣をシリカゲルカラムクロマトグラフィー(塩化メチレン−エタノール=30:1)で精製して、6-アセトキシメチルピリジン-2-カルボン酸 t-ブチルエステルを得た。
黄色油状物
1H-NMR (CDCl3) δ: 7.94 (1H, d, J = 7.5 Hz), 7.80 (1H, t, J = 7.5 Hz), 7.50 (1H, d, J= 7.5 Hz), 5.32 (2H, s), 2.17 (3H, s), 1.58 (9H, s)。
黄色粉末
1H-NMR (CDCl3) δ: 7.95 (1H, d, J = 7.5 Hz), 7.80 (1H, t, J = 7.5 Hz), 7.43 (1H, d, J= 7.5 Hz), 4.83 (2H, d, J = 5.1 Hz), 3.68 (1H, t, J= 5.1 Hz), 1.59 (9H, s)。
黄色粉末
1H-NMR (CDCl3) δ: 7.96 (1H, d, J = 7.5 Hz), 7.83 (1H, t, J = 7.5 Hz), 7.67 (1H, d, J= 7.5 Hz), 4.80 (2H, s), 1.59 (9H, s)。
(1) 6-メチルピコリン酸2.15gおよびt-ブチル 1-ピペラジンカルボキシレート3.21gをDMF45mLに溶解し、溶解液に氷冷下にHOBt4.24gを加えて15分間攪拌後、更にWSC3.0gを加えて室温で終夜撹拌した。反応混合液から溶媒を減圧留去後、該液に水を加えて酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸マグネシウムで乾燥後、溶媒を減圧留去した。残渣をシリカゲルカラムクロマトグラフィー(塩化メチレン−エタノール=30:1)で精製して、4.57gの4-(6-メチルピリジン-2-カルボニル)ピペラジン-1-カルボン酸 t-ブチルエステルを得た。
無色油状物
1H-NMR (CDCl3) δ: 7.67 (1H, t, J = 7.8 Hz), 7.35 (1H, d, J = 7.8 Hz), 7.21 (1H, d, J = 7.8 Hz), 3.77 (2H, t, J = 4.8 Hz), 3.55 (4H, t, J = 4.8 Hz), 3.46 (2H, t, J = 4.8 Hz), 2.57 (3H, s), 1.47 (9H, s)。
白色粉末
1H-NMR (CDCl3) δ: 7.31-7.17 (3H, m), 3.91 (1H, br s), 3.62-3.56 (4H, m), 3.45 (1H, br s), 3.26 (1H, br s), 3.13 (1H, br s), 2.51 (3H, s), 1.47 (9H, s)。
無色油状物
1H-NMR (CDCl3) δ: 7.82 (1H, t, J = 7.8 Hz), 7.60 (1H, d, J= 7.8 Hz), 7.40 (1H, d, J = 7.8 Hz), 5.22 (2H, s), 3.77 (2H, t, J = 4.8 Hz), 3.59-3.56 (4H, br), 3.69 (2H, t, J = 4.8 Hz), 2.17 (3H, s), 1.47 (9H, s)。
無色油状物
1H-NMR (CDCl3) δ: 7.81 (1H, t, J = 7.8 Hz), 7.55 (1H, d, J = 7.8 Hz), 7.34 (1H, d, J = 7.8 Hz), 4.79 (2H, s), 3.79 (2H, t, J = 4.8 Hz), 3.58-3.45 (6H, br), 1.47 (9H, s)。
無色油状物
1H-NMR (CDCl3) δ: 7.84 (1H, t, J = 7.8 Hz), 7.60 (1H, d, J = 7.8 Hz), 7.54 (1H, d, J = 7.8 Hz), 4.66 (2H, s), 3.76 (2H, br), 3.57-3.48 (6H, br), 1.47 (9H, s)。
(1) 6-ヒドロキシメチルピリジン-2-カルボアルデヒド15.3gを乾燥DMF250mLに溶解し、溶解液中に(t-ブトキシカルボニルメチレン)トリフェニルホスホラン50gを加え、室温で30分間攪拌した。反応混合物を氷水に投じ、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸マグネシウムで乾燥し、減圧濃縮した。残留物にヘキサン−酢酸エチル(2:1)の混液300mLを加え、不溶物を濾去した。濾液を減圧濃縮し、残留物をシリカゲルカラムクロマトグラフィー(ヘキサン−酢酸エチル=2:1)で精製して、16.86 gの3-(6-ヒドロキシメチルピリジン-2-イル)トランス-アクリル酸 t-ブチルエステルおよび5.69 gの3-(6-ヒドロキシメチルピリジン-2-イル)シス-アクリル酸 t-ブチルエステルを得た。
trans体 : 無色油状物
1H-NMR (CDCl3) δ: 7.70 (1H, t, J = 7.5 Hz), 7.58 (1H, d, J = 15.6 Hz), 7.31 (1H, d, J = 7.5 Hz), 7.18 (1H, d, J = 7.5 Hz), 6.88 (1H, d, J = 15.6 Hz), 4.77 (2H, d, J = 4.8 Hz), 3.88 (1H, t, J = 4.8 Hz), 1.54 (9H, s)。
cis体 : 無色油状物
1H-NMR (CDCl3) δ: 7.67 (1H, t, J = 7.8 Hz), 7.51 (1H, d, J = 7.8 Hz), 7.14 (1H, d, J = 7.8 Hz), 6.86 (1H, d, J = 12.6 Hz), 6.07 (1H, d, J = 12.6 Hz), 4.74 (2H, d, J = 4.8 Hz), 3.77 (1H, t, J = 4.8 Hz), 1.46 (9H, s)。
淡黄色油状物
1H-NMR (CDCl3) δ: 7.58 (1H, t, J = 7.5 Hz), 7.08 (1H, d, J = 7.5 Hz), 7.03 (1H, d, J = 7.5 Hz), 4.70 (2H, s), 3.10 (2H, t, J = 7.5 Hz), 2.72 (2H, t, J = 7.5 Hz), 1.42 (9H, s)。
淡黄色油状物
1H-NMR (CDCl3) δ: 7.58 (1H, t, J = 7.5 Hz), 7.26 (1H, d, J = 7.5 Hz), 7.09 (1H, d, J = 7.5 Hz), 4.51 (2H, s), 3.06 (2H, t, J = 7.5 Hz), 2.70 (2H, t, J = 7.5 Hz), 1.42 (9H, s)。
(1) 2-ブロモピリジン-6-メタノール2gを乾燥DMF10mLに溶解し、溶解液中にアクリル酸エチル1.73mL、塩化テトラ(n-ブチル)アンモニウム2.95g、炭酸水素ナトリウム1.78gおよびモレキュラーシーブス(Molecular Sieves 3A (1/16))2gを加え、アルゴン雰囲気下に、更に酢酸パラジウム(II)119mgを加え、混合物を80℃で5時間攪拌した。冷後、不溶物を濾去し、水を加えて酢酸エチルで抽出した。有機層を飽和食塩水で乾燥後、無水硫酸マグネシウムで乾燥し、減圧濃縮した。残渣をシリカゲルカラムクロマトグラフィー(ヘキサン−酢酸エチル=2:1)で精製して、1.39gの3-(6-ヒドロキシメチルピリジン-2-イル)トランス-アクリル酸 エチルエステルを得た。
淡黄色油状物
1H-NMR (CDCl3) δ: 7.71 (1H, t, J = 7.5 Hz), 7.66 (1H, d, J = 15.6 Hz), 7.32 (1H, d, J = 7.5 Hz), 7.20 (1H, d, J = 7.5 Hz), 6.96 (1H, d, J = 15.6 Hz), 4.78 (2H, d, J = 4.8 Hz), 4.29 (2H, q, J = 7.2 Hz), 3.85 (1H, t, J = 4.8 Hz), 1.35 (3H, t, J = 7.2 Hz)。
淡黄色油状物。
1H-NMR (CDCl3) δ: 7.58 (1H, t, J = 7.5 Hz), 7.08 (1H, d, J = 7.5 Hz), 7.02 (1H, d, J = 7.5 Hz), 4.71 (2H, d, J = 4.5 Hz), 4.14 (2H, q, J = 7.2 Hz), 4.01 (1H, t, J = 4.5 Hz), 3.15 (2H, t, J = 7.5 Hz), 2.80 (2H, t, J = 7.5 Hz), 1.24 (3H, t, J = 7.2 Hz)。
(1) アクリル酸エチルに代えてアクリル酸メチルを用いて、参考例11-(1)に記載の方法と同様にして、3-(6-ヒドロキシメチルピリジン-2-イル)トランス-アクリル酸 メチルエステルを得た。
淡黄色粉末
1H-NMR (CDCl3) δ: 7.72 (1H, t, J = 7.5 Hz), 7.68 (1H, d, J = 15.6 Hz), 7.32 (1H, d, J = 7.5 Hz), 7.21 (1H, d, J = 7.5 Hz), 6.97 (1H, d, J = 15.6 Hz), 4.78 (2H, d, J = 4.2 Hz), 3.85 (1H, t, J = 4.2 Hz), 3.83 (3H, s)。
淡褐色油状物。
1H-NMR (CDCl3) δ: 7.58 (1H, t, J = 7.5 Hz), 7.09 (1H, d, J = 7.5 Hz), 7.03 (1H, d, J = 7.5 Hz), 4.71 (2H, s), 4.01 (1H, br s), 3.69 (3H, s), 3.15 (2H, t, J = 7.2 Hz), 2.81 (2H, t, J = 7.2 Hz)。
(1) 6-ヒドロキシメチルピリジン-2-カルボアルデヒド2.95gおよび2−ホスホノプロピオン酸トリエチル5.12gを乾燥DMF20mLに溶解し、溶解液中にナトリウムメトキシド1.30gのメタノール10mL溶液を滴下し、室温で20分間攪拌した。反応混合物を氷水に投じ、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸マグネシウムで乾燥し、減圧濃縮した。残留物をシリカゲルカラムクロマトグラフィー(ヘキサン−酢酸エチル=1:1)で精製して、2.42 gの(E)-3-(6-ヒドロキシメチルピリジン-2-イル)-2-メチルアクリル酸 エチルエステルを得た。
無色油状物
1H-NMR (CDCl3) δ: 7.71 (1H, t, J = 7.8 Hz), 7.63 (1H, q, J = 1.5 Hz), 7.29 (1H, d, J = 7.8 Hz), 7.14(1H, d, J = 7.8 Hz), 4.79 (2H, d, J = 4.8 Hz), 4.29 (2H, q, J = 7.2 Hz), 3.84 (1H, t, J = 4.8 Hz), 2.35 (3H, d, J = 1.5 Hz), 1.36 (3H, t, J = 7.2 Hz)。
無色油状物
1H-NMR (CDCl3) δ: 7.57 (1H, t, J = 7.5 Hz), 7.04 (1H, d, J = 7.5 Hz), 7.02 (1H, d, J = 7.5 Hz), 4.70 (2H, br s), 4.11 (2H, q, J = 7.2 Hz), 3.22 (1H, dd, J = 14.1, 7.8 Hz), 3.05 (1H, sextet, J = 6.3 Hz), 2.88 (1H, dd, J = 14.1, 6.3 Hz), 1.27-1.16 (6H, m)。
参考例10-(1)に記載の3-(6-ヒドロキシメチルピリジン-2-イル)トランス-アクリル酸 t-ブチルエステル(トランス体)2gと四臭化炭素4.23gとを塩化メチレンに溶解させて調製した溶液20mLに氷冷下に、トリフェニルホスフィン2.68gを少量ずつ加え、同温で15分間攪拌した。反応液を分液ロートに移し、クロロホルムで希釈して飽和重曹水および飽和食塩水で洗い、無水硫酸マグネシウムで乾燥後、減圧濃縮した。残渣をシリカゲルカラムクロマトグラフィー(ヘキサン−酢酸エチル=10:1)で精製して、2.23gの3-(6-ブロモメチルピリジン-2-イル)トランス-アクリル酸 t-ブチルエステルを得た。
淡黄色粉末
1H-NMR (CDCl3) δ: 7.70 (1H, t, J = 7.8 Hz), 7.56 (1H, d, J = 15.6 Hz), 7.41 (1H, d, J = 7.8 Hz), 7.32 (1H, d, J = 7.8 Hz), 6.87 (1H, d, J = 15.6 Hz), 4.54 (2H, s), 1.53 (9H, s)。
(1) 4-ペンチノイン酸1.03gおよびN-メチルピペラジン1.0 gをDMF30 mLに溶解し、溶解液に氷冷下に攪拌しながらHOBt1.6gを加えた。同温度で15分間撹拌後、更にWSC2.3gを加え、室温で終夜撹拌した。反応混合物からDMFを減圧留去後、残渣に水を加え酢酸エチル抽出した。有機層を飽和食塩水で洗浄し、無水硫酸マグネシウムで乾燥後、溶媒を留去した。残渣をシリカゲルカラムクロマトグラフィー(塩化メチレン−メタノール−トリエチルアミン=600:20:1)で精製して、510mgの1-(4-メチルピペラジン-1-イル)ペンタ-4-イン-1-オンを得た。
無色油状物
1H-NMR (CDCl3) δ: 3.64 (2H, t, J = 5.1 Hz), 3.48 (2H, t, J = 5.1 Hz), 2.59-2.52 (4H, m), 2.41-2.35 (4H, m), 2.30 (3H, s), 1.97 (1H, s)。
黄色油状物
1H-NMR (CDCl3) δ: 7.62 (1H, t, J = 7.8 Hz), 7.27 (1H, d, J = 7.8 Hz), 7.18 (1H, d, J = 7.8 Hz), 4.73 (2H, s), 3.67 (2H, t, J = 6.6 Hz), 3.53(2H, t, J = 6.6 Hz), 2.84-2.78 (2H, m), 2.72-2.67 (2H, m), 2.43-2.38 (4H, m), 2.30 (3H, s)。
(1) 200mLの丸底フラスコに、2-ブロモピリジン-6-メタノール3.49g、4-ペンチノイン酸 t-ブチルエステル3.0g、BHT 190mg、よう化銅(I)1.17g、テトラキス(トリフェニルホスフィン)パラジウム(0)877mg、t-ブチルアミン2.72gおよびDMF56 mLを加え、アルゴン雰囲気下に混合物を80℃で6時間撹拌した。反応混合物からDMFを減圧留去後、飽和炭酸水素ナトリウム水溶液を加えて酢酸エチルで抽出し、有機層を飽和食塩水で洗浄し、無水硫酸マグネシウムで乾燥後、溶媒を留去した。残渣をシリカゲルカラムクロマトグラフィー(n−ヘキサン−酢酸エチル=2:1)で精製して、2.76 gの5-(6-ヒドロキシメチルピリジン-2-イル)ペンタ-4-イン酸 t-ブチルエステルを得た。
黄色油状物
1H-NMR (CDCl3) δ: 7.61 (1H, t, J = 7.8 Hz), 7.28 (1H, d, J = 7.8 Hz), 7.17 (1H, d, J = 7.8 Hz), 4.72 (2H, d, J = 5.1 Hz), 3.32 (1H, t, J = 5.1 Hz), 2.75 (2H, t, J = 7.2 Hz), 2.57 (2H, t, J = 7.2 Hz), 1.45 (12H, s)。
黄色油状物
1H-NMR (CDCl3) δ: 7.57 (1H, t, J = 7.8 Hz), 7.02 (2H, t, J = 7.8 Hz), 4.71 (2H, s), 2.80 (2H, t, J = 7.2 Hz), 2.56 (2H, t, J = 7.2 Hz), 1.82-1.60 (4H, m), 1.42 (12H, s)。
黄色油状物
1H-NMR (CDCl3) δ: 7.65 (1H, t, J = 7.8 Hz), 7.30 (1H, d, J = 7.8 Hz), 7.13 (1H, d, J = 7.8 Hz), 5.29 (2H, s), 3.08 (3H, s), 2.80 (2H, t, J = 7.2 Hz), 2.25 (2H, t, J = 7.2 Hz), 1.75-1.50 (4H, m), 1.44 (12H, s)。
(1) アクリル酸エチルに代えてエチルビニルケトンを用いて、参考例11に記載の方法と同様にして、(E)-1-(6-ヒドロキシメチルピリジン-2-イル)ペンタ-1-エン-3-オンを得た。
無色油状物
1H-NMR (CDCl3) δ: 7.72 (1H, t, J = 7.5 Hz), 7.55 (1H, d, J = 15.6 Hz), 7.36 (1H, d, J = 7.5 Hz), 7.23 (1H, d, J = 15.6 Hz), 7.22 (1H, d, J = 7.5 Hz), 4.79 (2H, d, J = 4.5 Hz), 3.84 (1H, br t, J = 4.5 Hz), 2.74 (2H, q, J = 7.2 Hz), 1.18 (3H, t, J = 7.2 Hz)。
淡褐色油状物。
1H-NMR (CDCl3) δ: 7.57 (1H, t, J = 7.8 Hz), 7.09 (1H, d, J = 7.8 Hz), 7.02 (1H, d, J = 7.8 Hz), 4.70 (2H, s), 3.94 (1H, br s), 3.09 (2H, t, J = 6.9 Hz), 2.92 (2H, t, J = 6.9 Hz), 2.47 (2H, q, J = 7.2 Hz), 1.06 (3H, t, J = 7.2 Hz)。
MeOおよびOMe: メトキシ基、
Me: メチル基
Et: エチル基
AcOおよびOAc: アセチルオキシ基、
TBDMS: tert-ブチルジメチルシリル基、
OEtおよびEtO: エトキシ基、
OtBuおよびtBuO: tert-ブチルオキシ基、
Ac: アセチル基、
tBuおよびt-Bu: tert-ブチル基
n-Pr: n-プロピル基、
iPrおよびi-Pr: イソプロピル基、
Ph: フェニル基
n-Bu: n-ブチル基
i-Bu: 2-メチルプロピル基
白色粉末
1H-NMR (DMSO-d6) δ: 10.2 (1H, s), 8.51 (1H, d, J = 4.8 Hz), 7.83 (2H, d, J = 8.4Hz), 7.75-7.70 (3H, m), 7.54 (1H, d, J = 7.8Hz), 7.26 (1H, dd, J = 6.6, 4.8Hz), 4.50 (2H, s), 2.08 (3H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.2 (1H, s), 7.83 (2H, d, J = 8.7 Hz), 7.72 (2H, d, J = 8.7 Hz), 7.60 (1H, t, J= 7.5 Hz), 7.33 (1H, d, J = 7.5 Hz), 7.12 (1H, d, J = 7.5 Hz), 4.44 (2H, s), 2.45 (3H, s), 2.09(3H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.23 (1H, s), 8.34 (1H, s), 7.60-8.20 (2H, br s), 7.84 (2H, d, J = 8.7 Hz), 7.72 (2H, d, J = 8.7 Hz), 7.54 (1H, d, J = 7.8 Hz), 7.43 (1H, d, J = 7.8 Hz), 4.46 (2H, s), 2.26 (3H, s), 2.09 (3H, s)。
淡黄色粉末
1H-NMR (DMSO-d6) δ: 10.24 (1H, s), 8.62 (1H, s), 7.65-8.25 (2H, br s), 7.84 (2H, d, J = 8.7 Hz), 7.73 (2H, d, J = 8.7 Hz), 7.36 (1H, s), 7.00 (1H, d, J = 7.8 Hz), 4.56 (2H, s), 2.26 (3H, s), 2.09 (3H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.24 (1H, s), 8.34 (1H, d, J = 4.8 Hz), 7.70-8.25 (2H, br s), 7.87 (2H, d, J = 8.7 Hz), 7.73 (2H, d, J = 8.7 Hz), 7.60 (1H, d, J = 7.5 Hz), 7.19-7.24 (1H, m), 4.61 (2H, s), 2.36 (3H, s), 2.09 (3H, s)。
白色粉末
1H-NMR (CDCl3) δ: 10.25 (1H, brs), 7.83 (2H, d, J = 7 Hz), 7.73 (2H, d, J = 6 Hz), 7.62 (1H, t, J = 6 Hz), 7.32 (1H, d, J = 6 Hz), 7.13 (1H, d, J = 6 Hz), 5.10 (1H, q, J = 6 Hz), 2.47 (3H, s), 2.09 (3H, s),1.69 (3H, d, J = 6 Hz)。
白色粉末
1H-NMR (CDCl3)δ: 8.40 (1H, brs), 7.94 (2H, d, J = 6 Hz), 7.63 (2H, d, J = 6 Hz), 7.52 (1H, t, J = 6 Hz), 7.22 (1H, d, J = 6 Hz), 7.00 (1H, d, J = 6 Hz), 5.79 (1H, brs), 5.03 (1H, t, J = 6 Hz), 2.55 (3H, s), 2.21 (3H, s), 2.00-2.15 (2H, m), 1.20-1.45 (4H, m), 0.86 (3H, t, J = 6 Hz)。
淡黄色粉末
1H-NMR (DMSO-d6) δ: 7.48-7.98 (2H, br s), 7.74 (2H, d, J = 8.7 Hz), 7.60 (1H, t, J = 7.8 Hz), 7.32 (1H, d, J = 7.8 Hz), 7.12 (1H, d, J = 7.8 Hz), 6.61 (2H, d, J = 8.7 Hz), 5.90 (2H, s), 4.44 (2H, s), 2.45 (3H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.16 (1H, s), 7.84 (2H, d, J = 8.7 Hz), 7.74 (2H, d, J = 8.7Hz), 7.61 (1H, t, J = 7.8 Hz), 7.33 (1H, d, J = 7.8 Hz), 7.12 (1H, d, J = 7.8 Hz), 4.45 (2H, s), 2.45 (3H, s), 2.37 (2H, q, J = 8.7Hz), 1.10 (3H, t, J = 7.5 Hz)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.43 (1H, s), 7.79-7.89 (4H, m), 7.61 (1H, t, J = 7.8 Hz), 7.33 (1H, d, J = 7.8 Hz), 7.12 (1H, d, J = 7.8 Hz), 6.42-6.52 (1H, m), 6.31 (1H, dd, J = 16.8, 2.1 Hz), 5.81 (1H, dd, J = 9.9, 2.1 Hz), 4.45 (2H, s), 2.45 (3H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.17 (1H, s), 7.65-8.20 (2H, br s), 7.83 (2H, d, J = 8.7 Hz), 7.74 (2H, d, J = 8.7 Hz), 7.61 (1H, t, J = 7.8 Hz), 7.33 (1H, d, J = 7.8 Hz), 7.12 (1H, d, J = 7.8 Hz), 4.45 (2H, s), 2.45 (3H, s), 2.33 (2H, t, J = 7.5Hz), 1.63 (3H, sext, J = 7.5Hz), 0.93 (3H, t, J = 7.5Hz)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.53 (1H, s), 7.80-8.01 (6H, m), 7.51-7.70 (4H, m), 7.35 (1H, d, J = 7.5 Hz), 7.13 (1H, d, J = 7.5Hz), 4.47 (2H, s), 2.46 (3H, s)。
黄色粉末
1H-NMR (DMSO-d6) δ: 10.01 (1H ,s), 7.83 (2H, d, J = 8.7 Hz), 7.61 (1H, t, J = 7.5 Hz), 7.60 (2H, d, J = 8.7 Hz), 7.33 (1H, d, J = 7.5 Hz), 7.12 (1H, d, J = 7.5 Hz), 4.45 (2H, s), 3.70 (3H, s), 2.45 (3H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.2 (1H, s), 7.82 (2H, d, J = 8.7 Hz), 7.72-7.67 (3H, m), 7.40 (1H, d, J = 7.8 Hz), 7.31 (1H, d, J = 7.8 Hz), 4.47 (2H, s), 3.57 (4H, br t), 2.39 (4H , br t), 2.08 (3H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.2 (1H, s), 7.83 (2H, d, J= 8.7 Hz),, 7.71 (2H, d, J = 8.7 Hz), 7.66 (1H, t, J = 7.2 Hz), 7.33 (1H, d, J= 7.2 Hz), 7.15 (1H, d, J= 7.2 Hz), 4.46 (2H, s), 3.55-3.52 (4H, m), 2.86 (2H, t, J= 7.2 Hz), 2.60 (2H, t, J= 7.2 Hz), 2.39 (4H, br t), 2.03 (3H, s)。
黄色粉末
1H-NMR (DMSO-d6) δ: 10.2 (1H, s), 7.83 (2H, d, J= 8.7 Hz), 7.71 (2H, d, J = 8.7 Hz), 7.61 (1H, t, J= 7.5 Hz), 7.32 (1H, d, J= 7.5 Hz), 7.12 (1H, d, J= 7.5 Hz), 4.40 (2H, s), 3.64-3.50 (4H, m), 2.70 (2H, t, J= 7.5 Hz), 2.40-2.24 (6H, m), 2.08 (3H, s), 2.49-2.45 (2H, m) 。
白色粉末
1H-NMR (DMSO-d6) δ: 10.2 (1H, s), 7.83 (2H, d, J = 8.7 Hz), 7.72-7.70 (3H, m), 7.40 (1H, d, J = 7.5 Hz), 7.32 (1H, d, J = 7.5 Hz), 4.47 (2H, s), 3.57 (2H, s), 2.50-2.35 (8H , m), 2.20 (3H, s), 1.38 (9H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.3 (1H, s), 9.42 (1H, br s), 7.89-7.81 (3H, m), 7.73 (2H, d, J= 8.7Hz), 7.63 (1H, d, J = 7.5Hz), 7.52 (1H, d, J= 7.5 Hz), 4.55 (2H, s), 3.37-3.25 (10H, m), 2.03 (3H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.2 (1H, s), 7.83 (2H, d, J = 8.7 Hz), 7.72-7.70 (3H, m), 7.44-7.32 (7H, m), 4.48 (2H, s), 3.60 (2H, s), 2.08(3H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 7.98 (2H, d, J = 8.7 Hz), 7.64 (2H, d, J= 8.7 Hz), 7.58 (1H, t, J = 7.5Hz), 7.53-7.50 (2H, m), 7.42-7.29 (5H, m), 4.54 (2H, s), 3.75 (2H, s), 2.61-2.48 (10H , m), 2.20 (3H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.2 (1H, s), 7.83 (2H, d, J = 8.7 Hz), 7.73-7.70 (3H, m), 7.40 (1H, d, J = 7.5 Hz), 7.32 (1H, d, J = 7.5 Hz), 4.48 (2H, s), 3.59 (2H, s), 3.43 (2H , br t ), 3.36-3.33 (4H, m), 3.08 (2H, s), 2.49-2.27 (10H, m), 2.12 (3H, s), 2.08 (3H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.2 (1H, s), 7.97 (1H, d, J= 8.4 Hz),, 7.83 (2H, d, J = 8.7 Hz), 7.73-7.68 (3H, m), 7.53 (1H, t, J= 7.2 Hz), 7.43-7.32 (3H, m), 6.96 (1H, d, J= 8.7 Hz), 4.47 (2H, s), 3.78 (3H, s), 3.62 (3H, s), 3.48-3.32 (2H, m), 2.49-2.45 (4H, m), 2.08 (3H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.2 (1H, s), 7.83 (2H, d, J = 9.0 Hz), 7.72-7.68 (3H, m), 7.42 (1H, d, J = 7.5 Hz), 7.33 (1H, d, J = 7.5 Hz), 4.48 (2H, s), 3.59 (2H, s), 3.49-3.41 (4H, m), 3.15 (2H , br s), 2.48-2.42 (4H, m), 2.21 (6H, s), 2.08 (3H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.2 (1H, s), 7.83 (2H, d, J= 8.7 Hz),, 7.74-7.68 (3H, m), 7.43 (1H, t, J = 7.5 Hz), 7.33 (1H, d, J= 7.5 Hz), 4.47 (2H, s), 3.60 (2H, s), 3.44-3.34 (4H, m), 2.51-2.50 (4H, m), 2.43-2.37 (4H, m), 2.09 (3H, s), 1.58 (4H, br s), 1.43 (2H, br t)。
白色粉末
1H-NMR (CD3OD) δ: 7.90-7.81 (3H, m), 7.73 (2H, d, J = 8.7 Hz), 7.69 (2H, d, J = 7.8 Hz), 7.43 (1H, t, J = 7.8 Hz), 4.64 (2H, s), 4.55 (2H, s), 4.42 (2H, s), 3.92 (1H, br s), 3.77-3.72 (3H, m), 3.58-3.51 (2H, m), 3.44-3.31 (2H, m), 3.29-3.14 (2H, m), 2.16 (3H, s), 2.10-2.06 (2H, m), 1.36-1.31 (2H, m)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.2 (1H, s), 7.86 (1H, t, J= 7.8 Hz), 7.79 (2H, d, J = 9.0 Hz), 7.70 (2H, d, J = 9.0 Hz), 7.62 (1H, d, J= 7.8 Hz), 7.47 (1H, d, J= 7.8 Hz), 4.53 (2H, s), 3.63 (4H, br t), 3.49-3.44 (2H, m), 2.08 (3H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 7.82-7.72 (7H, m), 4.55 (2H, s), 2.08 (3H, S), 1.54 (9H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.2 (1H, s), 7.89 (1H, t, J = 7.8 Hz), 7.83 (2H, d, J = 8.7 Hz), 7.75 (2H, d, J = 8.7 Hz), 7.63 (1H, d, J = 7.8 Hz), 7.47 (1H, d, J = 7.8 Hz), 4.53 (2H, s), 3.60-3.56 (2H, br), 3.45-3.31 (6H, br), 2.09 (3H, s), 1.40 (12H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.2 (1H, s), 9.16 (2H, br), 7.90 (1H, t, J= 7.8 Hz), 7.80 (2H, d, J= 8.7 Hz), 7.72 (2H, d, J= 8.7 Hz), 7.69 (1H, d, J= 7.8 Hz), 7.55 (1H, d, J= 7.8 Hz), 4.54 (2H, s), 3.86 (2H, br), 3.70 (2H, br), 3.20-3.10 (4H, br), 2.09 (3H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.25 (1H, s), 8.25-7.49 (2H, br s), 7.98 (1H, t, J = 7.5 Hz), 7.83 (2H, d, J = 8.7 Hz), 7.73 (2H, d, J = 8.7 Hz), 7.64 (1H, d, J = 7.5 Hz), 7.53 (1H, br s), 7.33 (1H, d, J = 7.5 Hz), 4.54 (2H, s), 4.29 (2H, d, J = 5.7 Hz), 2.09 (3H, s), 1.40 (9H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.24 (1H, s), 8.36 (1H, t, J = 6.0 Hz), 8.25-7.65 (2H, br s), 7.85 (2H, d, J = 8.7 Hz), 7.72-7.66 (3H, m), 7.41 (1H, d, J = 7.5 Hz), 7.14 (1H, d, J = 7.5 Hz), 4.48 (2H, s), 4.38 (2H, d, J = 6.0 Hz), 2.94 (2H, s), 2.24 (6H, s), 2.09 (3H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.25 (1H, s), 8.25-7.65 (2H, br s), 7.84 (2H, d, J = 8.7 Hz), 7.75-7.65 (3H, m), 7.29-7.40 (2H, m), 4.47 (2H, s), 3.78 (2H, s), 2.09 (3H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.24 (1H, s), 8.40 (1H, t, J = 6.0 Hz), 8.25-7.65 (2H, br s), 7.85 (1H, d, J = 8.7 Hz), 7.74-7.66 (3H, m), 7.41 (1H, d, J = 7.5 Hz), 7.12 (1H, d, J = 7.5 Hz), 4.47 (2H, s), 4.31 (2H, d, J = 6.0 Hz), 2.32-2.38 (6H, m), 2.20 (2H, t, J = 7.2 Hz), 2.09 (3H, s), 1.75-1.57 (6H, m)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.24 (1H, s), 7.84 (2H, d, J = 8.4 Hz), 7.75-7.69 (3H, m), 7.43 (1H, d, J = 7.5 Hz), 7.05 (1H, d, J = 7.5 Hz), 4.48 (3H, s), 4.43 (2H, s), 2.85 (3H, s) 2.09 (3H, s), 1.51-1.25 (9H, m)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.24 (1H, s), 7.65-8.25 (2H, br s), 7.84 (2H, d, J = 8.7 Hz), 7.72-7.66 (3H, m), 7.41 (1H, d, J = 7.8 Hz), 7.30 (1H, d, J = 7.8 Hz), 4.48 (2H, s), 3.74 (2H, s), 2.31 (3H, s), 2.09 (3H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.23 (1H, s), 8.22-7.66 (2H, br s), 7.86-7.65 (5H, m), 7.47-7.39 (1H, m), 7.13-7.01 (1H, m), 4.71-4.42 (4H, m), 3.05-2.78 (3H, m), 2.45-2.20 (8H, m), 2.09 (3H, s), 1.75-1.55 (6H, m)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.29 (1H, s), 8.73-8.65 (1H, m), 8.25-7.65 (2H, br s), 7.84 (2H, d, J = 9 Hz), 7.81-7.70 (3H, m), 7.50-7.45 (1H, m), 7.23-7.11 (1H, m), 6.20-5.79 (3H, m), 4.51-4.32 (4H, m), 2.10 (3H, s)。
淡黄色油状物
1H-NMR(DMSO-d6)δ: 10.2 (1H, s), 7.83 (2H, d, J= 8.7 Hz),, 7.71 (2H, d, J = 8.7 Hz), 7.66 (1H, t, J = 7.2 Hz), 7.33 (1H, d, J= 7.2 Hz), 7.15 (1H, d, J= 7.2 Hz), 4.46 (2H, s), 3.55-3.52 (4H, m), 2.86 (2H, t, J= 7.2 Hz), 2.60 (2H, t, J= 7.2 Hz), 2.39 (4H, br t), 2.03 (3H, s)。
白色粉末
1H-NMR(DMSO-d6)δ: 10.24 (1H, s), 8.25-7.65 (2H, br s), 7.86 (2H, d, J = 8.7 Hz), 7.74-7.65 (3H, m), 7.38 (1H, d, J = 7.5 Hz), 7.17-7.10 (2H, m), 4.47 (2H, s), 4.31 (2H, d, J = 6.0 Hz), 3.35-3.30 (4H, m), 2.31-2.24 (4H, m), 2.37(3H, s), 2.10 (3H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.23 (1H, s), 7.65-8.20 (5H, m), 7.46 (1H, d, J = 7.8 Hz), 7.33 (1H, d, J = 7.8 Hz), 4.48 (2H, s), 4.22 (2H, d, J = 6.3 Hz), 2.94-3.01 (2H, m), 2.09 (3H, s), 1.55-1.70 (2H, m), 0.89 (3H, t, J = 7.5 Hz)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.23 (1H, s), 7.65-8.20 (5H, m), 7.49 (1H, d, J = 7.8 Hz), 7.27 (1H, d, J = 7.8 Hz), 4.50 (2H, s), 4.40 (2H, s), 2.77-3.32 (2H, m), 2.79 (3H, s), 2.09 (3H, s), 1.61-1.76 (3H, m), 0.96 (3H, t, J = 7.2 Hz)。
淡黄色粉末
1H-NMR (DMSO-d6) δ: 7.83 (2H, d, J = 8.7 Hz), 7.72 (2H, d, J = 8.7 Hz), 7.63 (1H, t, J = 7.5 Hz), 7.35 (1H, d, J = 7.5 Hz), 7.14 (1H, d, J = 7.5 Hz), 4.45 (2H, s), 2.94 (2H, t, J = 7.5Hz), 2.61 (2H, t, J = 7.5 Hz), 2.09 (3H, s), 1.34 (9H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.23 (1H, s), 7.26-8.20 (2H, br s) 7.83 (2H, d, J = 8.7 Hz), 7.72 (2H, d, J = 8.7 Hz), 7.63 (1H, t, J = 7.8 Hz), 7.35 (1H, d, J = 7.8 Hz) 7.15 (1H, d, J = 7.8 Hz) 4.45 (2H, s), 4.03 (2H, q, J = 7.2 Hz), 2.98 (2H, t, J = 7.2 Hz), 2.70 (2H, t, J = 7.2 Hz), 2.09 (3H, s), 1.14 (3H, t, J = 7.2 Hz)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.23 (1H, s), 8.20-7.60 (2H, br s), 7.83 (2H, d, J = 8.7 Hz), 7.72 (2H, d, J = 8.7 Hz), 7.63 (1H, t, J = 7.8 Hz), 7.35 (1H, d, J = 7.8 Hz), 7.15 (1H, d, J = 7.8 Hz), 4.45 (2H, s), 3.57 (3H, s), 2.96 (2H, t, J = 7.2 Hz), 2.74 (2H, t, J = 7.2 Hz), 2.09 (3H, s)。
淡黄色粉末
1H-NMR (CD3OD) δ: 8.38 (1H, t, J = 7.8 Hz), 8.05 (1H, d, J = 7.8 Hz), 7.82 (2H, d, J = 9.0 Hz), 7.81 (1H, d, J = 7.8 Hz), 7.72 (2H, d, J = 9.0 Hz), 4.69 (2H, s), 3.15 (2H, t, J = 6.9 Hz), 2.84 (2H, t, J = 6.9 Hz), 2.16 (3H, s)。
淡黄色粉末
1H-NMR (CD3OD) δ: 8.39 (1H, t, J = 7.8 Hz), 8.04 (1H, d, J = 7.8 Hz), 7.83 (1H, d, J = 7.8 Hz), 7.82 (2H, d, J = 8.7 Hz), 7.72 (2H, d, J = 8.7 Hz), 4.72 (2H, s), 3.65-3.40 (4H, m), 3.26-2.99 (8H, m), 2.91 (3H, s), 2.16 (3H, s)。
淡褐色粉末
1H-NMR (DMSO-d6) δ: 10.22 (1H, s), 7.82 (2H, d, J = 8.7 Hz), 7.79 (1H, t, J = 7.5 Hz), 7.70 (2H, d, J = 8.7 Hz), 7.60 (1H, d, J = 7.5 Hz), 7.55 (1H, d, J = 7.5 Hz), 7.53 (1H, d, J = 15.9 Hz), 6.78 (1H, d, J = 15.9 Hz), 4.53 (2H, s), 2.08 (3H, s), 1.48 (9H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.2 (1H, s), 7.82 (2H, d, J= 9.0 Hz), 7.76 (1H, d, J = 7.8 Hz), 7.70 (2H, d, J= 9.0 Hz), 7.61 (1H, d, J= 7.8 Hz), 7.51 (1H, d, J= 7.8 Hz), 7.46 (2H, s), 4.53 (2H, s), 3.57 (4H, br t), 2.31 (4H, br t), 2.19 (3H, s), 2.08 (3H, s) 。
淡黄色粉末
1H-NMR (CDCl3) δ: 7.99 (2H, d, J = 9.0 Hz), 7.64 (2H, d, J = 9.0 Hz), 7.50 (1H, t, J = 7.5 Hz), 7.28 (1H, d, J = 7.5 Hz), 6.99 (1H, d, J = 7.5 Hz), 5.82 (2H, br s), 4.52 (1H, d, J = 14.4 Hz), 4.44 (1H, d, J = 14.4 Hz), 4.13 (2H, q, J = 7.2 Hz), 3.17 (1H, dd, J = 13.8, 7.8 Hz), 3.08-3.00 (1H, m), 2.87 (1H, dd, J = 13.8, 6.0 Hz), 2.21 (3H, s), 1.26-1.12 (6H, m)。
無色粉末
1H-NMR (DMSO-d6) δ: 10.23 (1H, s), 7.83 (2H, d, J = 9.0 Hz), 7.71 (2H, d, J = 9.0 Hz), 7.63 (1H, t, J = 7.5 Hz), 7.36 (1H, d, J = 7.5 Hz), 7.12 (1H, d, J = 7.5 Hz), 4.47 (2H, s), 3.05 (1H, dd, J = 13.8, 6.9 Hz), 2.86 (1H, sext, J = 6.9 Hz), 2.71 (1H, dd, J = 13.8, 7.2 Hz), 2.09 (3H, s), 1.04 (3H, d, J = 6.9 Hz)。
淡黄色粉末
1H-NMR (DMSO-d6) δ: 10.24 (1H, s), 7.84 (2H, d, J = 9.0 Hz), 7.72 (2H, d, J = 9.0 Hz), 7.60 (1H, t, J = 7.5 Hz), 7.35 (1H, d, J = 7.5 Hz), 7.04 (1H, d, J = 7.5 Hz), 4.49 (1H, d, J = 13.8 Hz), 4.42 (1H, d, J = 13.8 Hz), 3.35-3.25 (5H, m), 2.97 (1H, dd, J = 17.1, 8.4 Hz), 2.69 (1H, dd, J = 17.1, 6.0 Hz), 2.54-1.91 (4H, m), 2.09 (6H, s), 1.04 (3H, d, J = 6.0 Hz)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.2 (1H, s), 7.83 (2H, d, J = 8.7 Hz), 7.73-7.67 (3H, m), 7.49 (1H, d, J = 7.5 Hz), 7.30 (1H, d, J = 7.5 Hz), 4.45 (2H, s), 3.38-3.32 (4H, m), 2.62 (4H, s), 2.29-2.21 (4H, m), 2.14 (3H, s), 2.09 (3H, s)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.2 (1H, s), 7.83 (2H, d, J = 8.4 Hz), 7.70 (2H, d, J = 8.4 Hz), 7.62 (1H, t, J = 7.5 Hz), 7.34 (1H, d, J = 7.5 Hz), 7.10 (1H, d, J = 7.5 Hz), 4.45 (2H, s), 2.69 (2H, t, J = 7.5 Hz), 2.19 (2H, t, J = 7.5 Hz), 2.08 (3H, s), 1.66-1.47 (4H, m), 1.37 (9H, s)。
白色粉末
1H-NMR (CDCl3) δ: 8.34 (1H, s), 7.90 (2H, d, J = 8.4 Hz), 7.67 (2H, d, J = 8.4 Hz), 7.52 (1H, t, J = 7.5 Hz), 7.31 (1H, d, J = 7.5 Hz), 7.01 (1H, d, J = 7.5 Hz), 5.71 (2H, s), 4.50 (2H, s), 3.62 (2H, t, J = 5.1 Hz), 3.50 (2H, t, J = 5.1 Hz), 2.82 (2H, t, J = 7.5 Hz), 2.44-2.34 (6H, m), 2.30 (3H, s), 2.20 (3H, s), 1.86-1.73 (4H, m)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.2 (1H, s), 7.83 (2H, t, J = 8.7 Hz), 7.72 (2H, d, J = 8.7 Hz), 7.64 (1H, t, J = 7.8 Hz), 7.34 (1H, d, J = 7.8 Hz), 7.12 (1H, d, J = 7.8 Hz), 4.46 (2H, s), 2.70 (2H, t, J = 7.5 Hz), 2.31-2.26 (8H, m), 2.09 (3H, s), 1.65-1.63 (2H, m), 1.52-1.49(2H, m), 0.97-0.90 (6H, m)。
白色粉末
1H-NMR(DMSO-d6)δ: 7.73 (2H, d, J = 8.7 Hz), 7.80-7.55 (2H, br s), 7.61 (1H, t, J = 7.8 Hz), 7.33 (1H, d, J = 7.8 Hz), 7.14 (1H, d, J = 7.8 Hz), 6.61 (2H, d, J = 8.7 Hz), 5.90 (2H, s), 4.45 (2H, s), 3.40-3.34 (4H, m), 2.94 (2H, t, J = 7.2 Hz), 2.70 (2H, t, J = 7.2 Hz), 2.25-2.19 (4H, m), 2.12 (3H, s)。
淡黄色粉末
1H-NMR(DMSO-d6)δ: 10.16 (1H, s), 8.20-7.64 (2H, br s), 7.84 (2H, d, J = 8.7 Hz), 7.74 (2H, d, J = 8.7 Hz), 7.62 (1H, t, J = 7.8 Hz), 7.34 (1H, d, J = 7.8 Hz) 7.14 (1H, d, J = 7.8 Hz), 4.46 (2H, s), 3.42-3.35 (4H, m), 2.94 (2H, t, J = 7.2 Hz), 2.70 (2H, t, J = 7.2 Hz), 2.37 (2H, q, J = 7.5 Hz), 2.20-2.16 (4H, m), 2.12 (3H, s), 1.10 (3H, t, J = 7.5 Hz)。
白色粉末
1H-NMR(DMSO-d6)δ: 10.24 (1H, s), 7.83 (2H, d, J = 8.7 Hz), 7.73 (2H, d, J = 8.7 Hz), 7.62 (1H, t, J = 7.2 Hz), 7.34 (1H, d, J = 7.2 Hz), 7.14 (1H, d, J = 7.2 Hz), 4.46 (2H, s), 3.40-3.35 (4H, m), 2.94 (2H, t, J = 7.5 Hz), 2.70 (2H, t, J = 7.5 Hz), 2.20-2.16 (4H, m), 2.12 (3H, s), 1.63 (2H, sext, J = 7.5 Hz), 0.93 (3H, t, J = 7.5 Hz)。
無色粉末
1H-NMR (DMSO-d6) δ: 10.24 (1H, s), 7.88 (1H, br t, J = 7.5 Hz), 7.83 (2H, d, J = 8.4 Hz), 7.72 (2H, d, J = 8.4 Hz), 7.62 (1H, t, J = 7.5 Hz), 7.35 (1H, d, J = 7.5 Hz), 7.12 (1H, d, J = 7.5 Hz), 6.77 (1H, br t, J = 7.5 Hz), 4.46 (2H, s), 3.05 (2H, q, J = 7.5 Hz), 2.98-2.90 (4H, m), 2.46 (2H, t, J = 7.5 Hz), 2.09 (3H, s)。
淡黄色粉末
1H-NMR (DMSO-d6) δ: 10.23 (1H, s), 8.12 (1H, br t, J = 7.5 Hz), 7.85 (2H, br s), 7.82 (2H, d, J = 8.7 Hz), 7.72 (2H, d, J = 8.7 Hz), 7.57 (1H, br d, J = 7.5 Hz), 7.34 (1H, br d, J = 7.5 Hz), 4.56 (2H, s), 3.29 (2H, q, J = 6.0 Hz), 3.07 (2H, t, J = 7.5 Hz), 2.85 (2H, q, J = 6.0 Hz), 2.59 (2H, t, J = 7.5 Hz), 2.09 (3H, s)。
淡黄色粉末
1H-NMR (CD3OD) δ: 8.38 (1H, t, J = 7.8 Hz), 8.05 (1H, d, J = 7.8 Hz), 7.83 (2H, d, J = 9.0 Hz), 7.82 (1H, d, J = 7.8 Hz), 7.72 (2H, d, J = 9.0 Hz), 4.73 (2H, s), 3.53 (2H, t, J = 6.0 Hz), 3.27-3.22 (4H, m), 2.90 (6H, s), 2.82 (2H, t, J = 6.0 Hz), 2.16 (3H, s)。
淡黄色粉末
1H-NMR (CD3OD) δ: 8.37 (1H, t, J = 8.1 Hz), 8.03 (1H, d, J = 8.1 Hz), 7.84 (1H, d, J = 8.1 Hz), 7.83 (2H, d, J = 9.0 Hz), 7.72 (2H, d, J = 9.0 Hz), 4.73 (2H, s), 3.72 (2H, t, J = 5.4 Hz), 3.32-3.21 (4H, m), 3.07 (3H, s), 3.02 (2H, t, J = 5.4 Hz), 2.92 (6H, s), 2.16 (3H, s)。
淡黄色粉末
1H-NMR (CD3OD) δ: 8.38 (1H, t, J = 7.8 Hz), 8.05 (1H, d, J = 7.8 Hz), 7.83 (2H, d, J = 9.0 Hz), 7.80 (1H, d, J = 7.8 Hz), 7.72 (2H, d, J = 9.0 Hz), 4.73 (2H, s), 3.23 (2H, t, J = 6.9 Hz), 3.10 (2H, t, J = 6.9 Hz), 2.87 (2H, t, J = 6.9 Hz), 2.85 (6H, s), 2.79 (2H, t, J = 6.9 Hz), 2.16 (3H, s), 1.89 (2H, quint, J = 6.9 Hz)。
淡黄色粉末
1H-NMR (CD3OD) δ: 8.36 (1H, t, J = 7.8 Hz), 8.01 (1H, d, J = 7.8 Hz), 7.84 (2H, d, J = 9.0 Hz), 7.82 (1H, d, J = 7.8 Hz), 7.72 (2H, d, J = 9.0 Hz), 4.72 (2H, s), 3.40 (2H, t, J = 6.9 Hz), 3.22 (2H, t, J = 6.9 Hz), 3.06 (3H, s), 3.06-2.98 (4H, m), 2.82 (6H, s), 2.16 (3H, s)。
1H-NMR (DMSO-d6) δ: 10.24 (1H, s), 8.25-7.61 (3H, m), 7.83 (2H, d, J = 8.7 Hz), 7.72 (2H, d, J = 8.7 Hz), 7.62 (1H, t, J = 7.8 Hz), 7.35 (1H, d, J = 7.5 Hz), 7.12 (1H, d, J = 7.5 Hz), 4.46 (2H, s) 3.17-3.12 (2H, m), 2.98-2.89 (2H, m), 2.49-2.45 (2H, m), 2.40-2.22 (6H, m), 2.09 (3H, s), 1.30-2.01 (6H, m)。
淡黄色粉末
1H-NMR (CD3OD) δ: 8.39 (1H, t, J = 8.1 Hz), 8.06 (1H, d, J = 8.1 Hz), 7.83 (2H, d, J = 9.0 Hz), 7.81 (1H, d, J = 8.1 Hz), 7.72 (2H, d, J = 9.0 Hz), 4.73 (2H, s), 3.51 (2H, t, J = 6.3 Hz), 3.30-3.19 (8H, m), 2.82 (2H, t, J = 6.3 Hz), 2.17 (3H, s), 1.29 (6H, t, J = 9.0 Hz)。
黄色粉末
1H-NMR (CD3OD) δ: 8.39 (1H, t, J = 7.8 Hz), 8.03 (1H, d, J = 7.8 Hz), 7.86 (2H, d, J = 9.0 Hz), 7.83 (1H, d, J = 7.8 Hz), 7.73 (2H, d, J = 9.0 Hz), 4.80 (2H, s), 3.64-3.47 (2H, m), 3.24 (2H, t, J = 6.3 Hz), 3.17-3.12 (1H, m), 2.99 (2H, t, J = 6.3 Hz), 2.98-2.89 (2H, m), 2.91 (3H, s), 2.79 (3H, s), 2.16 (3H, s), 2.10-1.76 (4H, m)。
無色粉末
1H-NMR (CD3OD) δ: 8.39 (1H, t, J = 7.2 Hz), 8.03 (1H, d, J = 7.2 Hz), 7.84 (2H, d, J = 8.7 Hz), 7.83 (1H, d, J = 7.2 Hz), 7.72 (2H, d, J = 8.7 Hz), 4.73 (2H, s), 4.58 (1H, br d, J = 12.6 Hz), 4.06 (1H, br d, J = 12.6 Hz), 3.64-3.53 (1H, m), 3.33-2.62 (8H, m), 2.16 (3H, s), 2.16-1.56 (4H, m), 1.35 (6H, t, J = 7.2 Hz)。
淡黄色粉末
1H-NMR (DMSO-d6) δ: 10.45 (1H, s), 8.27 (1H, t, J = 7.5 Hz), 7.93 (1H, t, J = 7.5 Hz), 7.81 (2H, d, J = 9.0 Hz), 7.76 (2H, d, J = 9.0 Hz), 7.74 (1H, d, J = 7.5 Hz), 4.76 (2H ,s), 4.46 (1H, br d, J = 13.2 Hz), 4.00 (1H, br d, J = 13.2 Hz), 3.35-3.17 (6H, m), 3.05-2.84 (4H, m), 2.56-2.48 (1H, m), 2.15-2.07 (2H ,m), 2.10 (3H, s), 1.97-1.35 (8H, m)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.24 (1H, s), 8.25-7.50 (2H, br s), 7.84 (2H, d, J = 8.7 Hz), 7.72 (2H, d, J = 8.7 Hz) 7.62 (1H, t, J = 7.8 Hz), 7.34 (1H, d, J = 7.8 Hz), 7.15 (1H, d, J = 7.8 Hz), 4.47 (2H, s), 3.85-4.70 (5H, m), 3.70-3.35 (1H, m), 3.01-2.62 (4H, m), 2.09 (3H, s), 1.80-1.05 (6H, m)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.2 (1H, s), 7.83 (2H, d, J = 8.4Hz), 7.71 (2H, d, J = 8.4 Hz), 7.62 (1H, t, J = 7.8 Hz), 7.34 (1H, d, J = 7.8 Hz), 7.15 (1H, d, J = 7.8 Hz), 4.45 (2H, s), 4.25-3.75 (3H, m), 2.94 (4H, m), 2.80-2.73 (2H, m), 2.48-2.20 (8H, m), 2.08 (3H, s), 1.42-1.32 (6H, m)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.2 (1H, s), 7.83 (2H, d, J = 8.4Hz), 7.71 (2H, d, J = 8.4 Hz), 7.62 (1H, t, J = 7.8 Hz), 7.34 (1H, d, J = 7.8 Hz), 7.16 (1H, d, J = 7.8 Hz), 4.46 (2H, s), 4.25-3.75 (3H, m), 2.94-2.73 (4H, m), 2.48-2.20 (13H, m), 2.08 (3H, s), 0.93 (3H, br t)。
白色粉末
1H-NMR (DMSO-d6) δ: 10.23 (1H, s), 7.83 (2H, d, J = 8.7 Hz), 7.71 (2H, d, J = 8.7 Hz), 7.62 (1H, t, J = 7.8 Hz), 7.34 (1H, d, J = 7.8 Hz), 7.16 (1H, d, J = 7.8 Hz), 4.46 (2H, s), 3.41-3.38 (4H, m), 3.30-3.25 (4H, m), 2.95 (2H, t, J = 7.5 Hz), 2.73 (2H, t, J = 7.5 Hz), 2.09 (3H, s), 1.39 (9H, s)。
淡黄色粉末
1H-NMR (CD3OD) δ: 8.34 (1H, t, J = 7.8 Hz), 8.00 (1H, d, J = 7.8 Hz), 7.83 (2H, d, J = 8.7 Hz), 7.79 (1H, d, J = 7.8 Hz), 7.71 (2H, d, J = 8.7 Hz), 4.70 (2H, s), 3.77-3.74 (4H, m), 3.29-3.16 (6H, m), 3.04 (2H, t, J = 6.6 Hz), 2.16 (3H, s)。
無色粉末
1H-NMR (CD3OD) δ: 8.39 (1H, t, J = 7.8 Hz), 8.05 (1H, d, J = 7.8 Hz), 7.86 (1H, d, J = 7.8 Hz), 7.83 (2H, d, J = 9.0 Hz), 7.73 (2H, d, J = 9.0 Hz), 4.73 (2H, s), 3.69-3.07 (20H, m), 2.17 (3H, s), 1.38 (6H, t, J = 7.2 Hz)。
無色粉末
1H-NMR (DMSO-d6) δ: 10.23 (1H, s), 7.65-8.20 (2H, br s), 7.84 (2H, d, J = 8.7 Hz), 7.72 (2H, d, J = 8.7 Hz), 7.62 (1H, t, J = 7.8 Hz), 7.34 (1H, d, J = 7.8 Hz), 7.14 (1H, d, J = 7.8 Hz), 4.47 (2H, s), 3.40-3.29 (4H, m), 2.97-2.71 (4H, m), 2.69-2.51 (2H, m), 2.49-2.42 (2H, m), 2.30-2.18 (6H, m) 2.09 (3H, s), 0.92 (12H, d, J = 6.3Hz)。
淡黄色粉末
1H-NMR (DMSO-d6+D2O) δ: 8.09 (1H, t, J = 7.8 Hz), 7.80 (2H, d, J = 9.0 Hz), 7.77 (1H, d, J = 7.8 Hz), 7.72 (2H, d, J = 9.0 Hz), 7.57 (1H, d, J = 7.8 Hz), 4.62 (2H, s), 3.58 (2H, t, J = 7.2 Hz), 3.65-3.11 (16H, m), 2.91 (2H, t, J = 7.2 Hz), 2.11 (3H, s), 1.99 (4H, br s)。
淡黄色粉末
1H-NMR (CD3OD) δ: 8.39 (1H, t, J = 8.1 Hz), 8.05 (1H, d, J = 8.1 Hz), 7.85 (1H, d, J = 8.1 Hz), 7.83 (2H, d, J = 8.7 Hz), 7.72 (2H, d, J = 8.7 Hz), 4.73 (2H, s), 4.00 (4H, br s), 3.72 (4H, br s), 3.66-3.27 (14H, m), 3.09 (2H, br s), 2.17 (3H, s)。
淡黄色粉末
1H-NMR (CD3OD) δ: 8.39 (1H, t, J = 8.1 Hz), 8.03 (1H, d, J = 8.1 Hz), 7.84 (3H, br d, J = 9.0 Hz), 7.72 (2H, d, J = 9.0 Hz), 4.74 (2H, s), 3.58-2.92 (18H, m), 2.88 (3H, s), 2.28-1.57 (5H, m), 2.17 (3H, s)。
淡黄色粉末
1H-NMR (CD3OD) δ: 8.38 (1H, t, J = 7.8 Hz), 8.02 (1H, d, J = 7.8 Hz), 7.84 (2H, d, J = 9.0 Hz), 7.84 (1H, d, J = 7.8 Hz), 7.72 (2H, d, J = 9.0 Hz), 4.72 (2H, s), 4.03-3.05 (12H, m), 2.89 (3H, s), 2.23-2.06 (2H, m), 2.16 (3H, s)。
淡黄色粉末
1H-NMR (CD3OD) δ: 8.40 (1H, t, J = 8.1 Hz), 8.08 (1H, d, J = 8.1 Hz), 7.83 (2H, d, J = 8.7 Hz), 7.82 (1H, d, J = 8.1 Hz), 7.72 (2H, d, J = 8.7 Hz), 4.72 (2H, s), 3.48-2.70 (12H, m), 2.85 (3H, s), 2.16 (3H, s)。
無色粉末
1H-NMR (DMSO-d6) δ: 10.23 (1H, s), 7.83 (2H, d, J = 9.0 Hz), 7.72 (2H, d, J = 9.0 Hz), 7.61 (1H, t, J = 7.5 Hz), 7.33 (1H, d, J = 7.5 Hz), 7.13 (1H, d, J = 7.5 Hz), 4.45 (2H, s), 2.93 (2H, t, J = 6.9 Hz), 2.81 (2H, t, J = 6.9 Hz), 2.46 (2H, q, J = 7.2 Hz), 2.09 (3H, s), 0.90 (3H, t, J = 7.2 Hz).
実施例42〜82で得た化合物の構造を下記表13〜表15に示す。
カラム:CAPCELL PAK C18 (UG 120 S-5, 20mm×50mm) (分取精製)
CAPCELL PAK C18 (UG 120 S-3, 3.0mm×50mm) (分析)
溶離液:0.05%TFA-MeCN, 0.05%TFA-H2Oの混合溶液(適宜溶媒比を変更)
流速:36 mL/min (分取精製)
1.8 mL/min (分析)
<LC/MS分析条件>
システム:Waters Alliance 2795, Waters ZQ
MS検出:ESI positive。
本実験は、文献(Klotz k.N. et al., Naunyn- Schmiedeberg's Arch. Pharmacol., (1998) 357, 1-9; Shryock J.C. et al., Molecular Pharmacology, (1998) 53, 886-893)に記載された方法を参考に以下の通り行った。
<比較化合物A>
本実験は文献(Shryock J.C. et al., Molecular Pharmacology, (1998) 53, 886-893; Ito H. et al., European Journal of Pharmacology, (1999) 365, 309-315)に記載された方法を参考にして以下の通り行った。即ち、雄性Wistarラット(日本チャールズリバー)の大脳皮質を摘出し、Tris buffer (50mM Tris-HCl : pH7.4)を加えてホモジナイズした後、遠心分離(1000×g、10min)した。上清を採取し、遠心分離(20,000×g、20min)した。上清を除去した後、沈殿物にTris bufferを加えて懸濁させ、再度遠心分離(20,000×g、20min)した。上清を除去後、沈殿物に2units/mL ADA(adenosine deaminase)を含むTris bufferを加えて懸濁させ、以後の試験に用いる細胞膜調製液を調製した。この液は使用まで-80℃で保存した。
被験化合物は10mMリン酸緩衝液(pH7.5)(以下点眼基剤という)を用いて、所定濃度の溶液または懸濁液に調製して試験に利用した。即ち、所定濃度に調製した際、完全に溶解しない被験化合物の場合は、その濃度の懸濁液として使用した。
Claims (10)
- 一般式(1):
R1は水素原子、低級アルキルカルボニル基、低級アルケニルカルボニル基、フェニルカルボニル基または低級アルコキシカルボニル基を示す。
R2は低級アルキレン基を示す。
R3は(1)水素原子、(2)低級アルキル基または下記基(3)〜基(12)のいずれかを示す。
Z1:(a1)低級アルキル基、(a2)アリール低級アルキル基、(a3)アミノアリール低級アルキル基、(a4)アリール低級アルケニル基、(a5)ヘテロアリール低級アルキル基、(a6)ヘテロアリール低級アルケニル基、(a7)ヘテロアリールアリール低級アルキル基、(a8)ヒドロキシ低級アルキル基、(a9)アリールオキシ低級アルキル基、(a10)アミノ低級アルキル基、(a11)アミノカルボニル低級アルキル基、(a12)低級アルキルカルボニル基、(a13)低級アルコキシ低級アルキルカルボニル基、(a14)アミノ低級アルキルカルボニル基、(a15)アリールカルボニル基、(a16)アリール低級アルキルカルボニル基、(a17)アリール低級アルケニルカルボニル基、(a18)アリールオキシ低級アルキルカルボニル基、(a19)ヘテロアリールカルボニル基、(a20)ヘテロアリール低級アルキルカルボニル基、(a21)ヘテロアリール低級アルケニルカルボニル基、(a22)ヘテロアリールオキシ低級アルキルカルボニル基、(a23)ヘテロアリールスルファニル低級アルキルカルボニル基、(a24)ヘテロアリールアリールカルボニル基、(a25)アリールスルファニル低級アルキルカルボニル基、(a26)アリールカルボニル低級アルキルカルボニル基、(a27)アリールアミノ低級アルキルカルボニル基、(a28)低級アルコキシカルボニル基、(a29)低級アルキルスルホニル基、(a30)アリールスルホニル基、(a31)ヘテロアリールスルホニル基、(a32)水素原子、(a33)飽和複素環を有する低級アルキル基、(a34)飽和複素環を有するカルボニル低級アルキル基、(a35)飽和複素環を有するアリール低級アルキル基、(a36)飽和複素環を有するカルボニル基、(a37)飽和複素環を有する低級アルキルカルボニル基、(a38)飽和複素環を有するアリールカルボニル基。
尚、上記(a3)、(a10)、(a11)および(a14)に記載の各基の一部を構成するアミノ基は、低級アルキル基、カルボニル基および低級アルキルカルボニル基からなる群から選ばれる置換基の1または2個で置換されていてもよく、上記(a2)、(a15)、(a16)、(a17)、(a18)、(a30)および (a35)に記載の各基の一部を構成するアリール基は、ハロゲン、水酸基、低級アルキル基、低級アルコキシ基、ハロゲノ低級アルコキシ基、アリール基、アリールオキシ基、メチレンジオキシ基、ジハロゲノメチレンジオキシ基、カルボキシル基、低級アルコキシカルボニル基、低級アルキルカルボニルオキシ基、ニトロ基、低級アルキルアミノ基、低級アルキルカルボニルアミノ基およびアミノスルホニル基からなる群から選ばれる置換基の1〜3個で置換されていてもよく、上記(a5)、(a19)〜(a24)および(a31)に記載の各基の一部を構成するヘテロアリール基は、ハロゲン、水酸基、低級アルキル基、ヒドロキシ低級アルキル基、ハロゲノ低級アルキル基、アリール基、ハロゲノアリール基、低級アルキルスルファニル基、アミノカルボニル基およびカルボキシル基からなる群から選ばれる置換基の1〜3個で置換されていてもよい。更に、上記(a33)〜(a38)に記載の各基の一部を構成する飽和複素環は、5-7員の含窒素飽和複素環基または該基に1乃至は2個のベンゼン環が縮合した基であって且つ該環を構成する窒素原子上に1個の低級アルキル基または低級アルキルカルボニル基を有していてもよく、また該環を構成する炭素原子上に1または2個のオキソ基を有していてもよい。
Z2:(b1)水素原子、(b2)低級アルコキシカルボニル基、(b3)アミノ低級アルキルカルボニル基、(b4)低級アルケニルカルボニル基、(b5)飽和複素環を有する低級アルキルカルボニル基、(b6)飽和複素環を有するピペリジノ低級アルキルカルボニル基、(b7)飽和複素環を有するカルボニル基および(b8)低級アルキルスルホニル基。
尚、上記(b3)に記載の各基の一部を構成するアミノ基は、1または2個の低級アルキル基で置換されていてもよい。更に、上記(b5)から(b7)に記載の各基の一部を構成する飽和複素環は、5-7員の含窒素飽和複素環基であって且つ該環を構成する窒素原子上に1個の低級アルキル基を有していてもよい。
Z3:(c1)水酸基、(c2)低級アルコキシ基、(c3)アミノ基、(c4)アミノ低級アルキルアミノ基、 (c5)ピペラジノ基、(c6)アミノ低級アルキルピペラジノ基、(c7)アミノカルボニル低級アルキルピペラジノ基、(c8)1,4-ジアゼパン-1-イル基、(c9)アミノ低級アルキル-1,4-ジアゼパン-1-イル基、(c10)ピペリジノ基、(c11)アミノピペリジノ基、(c12)アミノ低級アルキルアミノピペリジノ基、(c13)アミノ低級アルキルピペリジノ基、(c14)ピロリジノ基、(c15)飽和複素環を有するアミノ基、(c16)飽和複素環を有する低級アルキルアミノ基、(c17)飽和複素環を有するピペラジノ基、(c18)飽和複素環を有する低級アルキルピペラジノ基、(c19)飽和複素環を有するカルボニル低級アルキルピペラジノ基、(c20)飽和複素環を有する低級アルキル-1,4-ジアゼパン-1-イル基、(c21)飽和複素環を有するピペリジノ基および(c22)飽和複素環を有する低級アルキルモルホリノ基。
尚、上記(c3)のアミノ基、並びに(c4)、(c6)、(c7)、(c9)、(c11)、(c12)、(c13)、(c15)および(c16)に記載の各基の一部を構成するアミノ基は、低級アルキル基、ヒドロキシ低級アルキル基、アリール基、ヘテロアリール基、アリール低級アルキル基、アルキコキシアリール低級アルキル基、ヘテロアリール低級アルキル基および低級アルコキシカルボニル基からなる群から選ばれる置換基の1または2個で置換されていてもよく、上記(c11)に記載の基の一部を構成するアミノ基は、1個のアリール低級アルキルカルボニル基で置換されていてもよい。また上記(c5)のピペラジノ基および(c8)の1,4-ジアゼパン-1-イル基は、その4位に低級アルキル基、ヒドロキシ低級アルキル基、低級アルコキシ低級アルキル基、アリール基、低級アルキルアリール基、ヒドロキシアリール基、シアノアリール基、ハロゲノアリール基、アリール低級アルキル基、低級アルコキシアリール低級アルキル基、ハロゲノアリールオキシ低級アルキル基、ヘテロアリール基、低級アルキルへテロアリール基、ハロゲノ低級アルキルへテロアリール基、シアノへテロアリール基、ヘテロアリール低級アルキル基、低級アルコキシカルボニル基および低級アルキルカルボニル基からなる群から選ばれる置換基のいずれか1個を有していてもよい。更に、上記(c15)〜(c22)に記載の各基の一部を構成する飽和複素環は、5-7員の含窒素飽和複素環基であって、該基には1乃至2個のベンゼン環が縮合していてもよく、また該基は、これを構成する窒素原子上に低級アルキル基、アリール基、シアノアリール基、低級アルキルカルボニル基、ハロゲノ低級アルキルアリール基およびアリール低級アルキル基からなる群から選ばれる置換基のいずれか1個を有していてもよい。更に、上記(c5)のピペラジノ基、(c10)のピペリジノ基および(c15)〜(c22)に記載の各基の一部を構成する飽和複素環は、これらの環を構成する炭素原子上に水酸基、オキソ基、低級アルキル基、ヒドロキシ低級アルキル基、アリール基、アリール低級アルキル基、アミノカルボニル基および低級アルキルアミノ基からなる群から選ばれる置換基のいずれか1個を有していてもよい。]
で表される4-アミノ-5-シアノピリミジン誘導体またはその製剤学的に許容される塩。 - R2がメチレン基であり、R3が水素原子または低級アルキル基である請求項1に記載の4-アミノ-5-シアノピリミジン誘導体またはその製剤学的に許容される塩。
- R1が低級アルキルカルボニル基であり、R2がメチレン基であり、且つR3が基(3)または基(6)である請求項1に記載の4-アミノ-5-シアノピリミジン誘導体またはその製剤学的に許容される塩。
- R4が低級アルキレン基であり、且つZ1が(a2)、(a14)、(a15)、(a28)、(a32)および(a37)から選ばれるいずれかの基である請求項3に記載の4-アミノ-5-シアノピリミジン誘導体またはその製剤学的に許容される塩。
- R1が低級アルキルカルボニル基であり、R2がメチレン基であり、且つR3が基(4)、基(5)または基(7)(但し、Z1は低級アルコキシカルボニル基または水素原子を示す)である請求項1に記載の4-アミノ-5-シアノピリミジン誘導体またはその製剤学的に許容される塩。
- R1が低級アルキルカルボニル基であり、R2がメチレン基であり、且つR3が基(8)である請求項1に記載の4-アミノ-5-シアノピリミジン誘導体またはその製剤学的に許容される塩。
- R1が水素原子または低級アルキルカルボニル基であり、R2がメチレン基であり、且つR3が基(9)、基(10)または基(11)である請求項1に記載の4-アミノ-5-シアノピリミジン誘導体またはその製剤学的に許容される塩。
- R1が水素原子または低級アルキルカルボニル基であり、R2がメチレン基であり、且つR3が基(9)、基(10)または基(11)(但し、Z3は(c1)、(c2)、(c4)、(c5)、(c6)、(c7)、(c8)、(c10)、(c11)、(c15)、(c16)、(c18)、(c21)または(c22)を示す)である請求項1に記載の4-アミノ-5-シアノピリミジン誘導体またはその製剤学的に許容される塩。
- R1がアセチル基であり、R2がメチレン基であり、且つR3が基(9)(但し、Z3は(c4)、(c5)、(c6)、(c10)、(c11)、(c16)、(c18)、(c21)または(c22)を示す)である請求項1に記載の4-アミノ-5-シアノピリミジン誘導体またはその製剤学的に許容される塩。
- 下記1)〜19)から選択される請求項1-9のいずれかに記載の4-アミノ-5-シアノピリミジン誘導体またはその製剤学的に許容される塩。
1) N-{4-[6-アミノ-5-シアノ-2-(ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド、
2) N-{4-[6-アミノ-5-シアノ-2-(6-メチルピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド、
3) N-{4-[6-アミノ-5-シアノ-2-(6-{4-[2-(4-メチルピペラジン-1-イル)アセチル]ピペラジン-1-イルメチル}ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド、
4) N-[4-(6-アミノ-5-シアノ-2-{6-[3-(4-メチルピペラジン-1-イル)-3-オキソプロピル]ピリジン-2-イルメチルスルファニル}ピリミジン-4-イル)フェニル]アセトアミド、
5) 3-{6-[4-(4-アセチルアミノフェニル)-6-アミノ-5-シアノピリミジン-2-イルスルファニルメチル]ピリジン-2-イル}-N-(2-ジメチルアミノエチル)プロピオンアミド、
6) 3-{6-[4-(4-アセチルアミノフェニル)-6-アミノ-5-シアノピリミジン-2-イルスルファニルメチル]ピリジン-2-イル}-N-(2-ジメチルアミノエチル)-N-メチルプロピオンアミド、
7) 3-{6-[4-(4-アセチルアミノフェニル)-6-アミノ-5-シアノピリミジン-2-イルスルファニルメチル]ピリジン-2-イル}-N-(2-ジメチルアミノプロピル)-N-メチルプロピオンアミド、
8) 3-{6-[4-(4-アセチルアミノフェニル)-6-アミノ-5-シアノピリミジン-2-イルスルファニルメチル]ピリジン-2-イル}-N-(2-メチルピペリジン-1-イルエチル)プロピオンアミド、
9) 3-{6-[4-(4-アセチルアミノフェニル)-6-アミノ-5-シアノピリミジン-2-イルスルファニルメチル]ピリジン-2-イル}-N-(2-ジエチルアミノエチル)プロピオンアミド、
10) 3-{6-[4-(4-アセチルアミノフェニル)-6-アミノ-5-シアノピリミジン-2-イルスルファニルメチル]ピリジン-2-イル}-N-メチル-N-(1-メチルピペリジン-4-イル)プロピオンアミド、
11) N-(4-{6-アミノ-2-[6-(3-[1,4’]ビピペリジニル-1’-イル-3-オキソプロピル)ピリジン-2-イルメチルスルファニル]-5-シアノピリミジン-4-イル}フェニル)アセトアミド、
12) N-[4-(6-アミノ-5-シアノ-2-{6-[3-オキソ-3-(2-ピペリジン-1-イルメチルモルホリン-4-イル)プロピル]ピリジン-2-イルメチルスルファニル}ピリミジン-4-イル)フェニル]アセトアミド、
13) N-{4-[6-アミノ-5-シアノ-2-(6-{3-[2-(4-エチルピペラジン-1-イルメチル)モルホリン-4-イル]-3-オキソプロピル}ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド、
14) N-{4-[6-アミノ-5-シアノ-2-(6-{3-[4-(2-ジエチルアミノエチル)ピペラジン-1-イル]-3-オキソプロピル}ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド、
15) N-{4-[6-アミノ-5-シアノ-2-(6-{3-[4-(2-ジイソプロピルアミノエチル)ピペラジン-1-イル]-3-オキソプロピル}ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド、
16) N-{4-[6-アミノ-5-シアノ-2-(6-{3-オキソ-3-[4-(2-ピロリジン-1-イルエチル)ピペラジン-1-イル]プロピル}ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド、
17) N-{4-[6-アミノ-5-シアノ-2-(6-{3-[4-(2-モルホリン-4-イルエチル)ピペラジン-1-イル]-3-オキソプロピル}ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド、
18) N-{4-[6-アミノ-5-シアノ-2-(6-{3-[4-(2-ジエチルアミノエチル)ピペラジン-1-イル]-3-オキソプロピル}ピリジン-2-イルメチルスルファニル)ピリミジン-4-イル]フェニル}アセトアミド、
19) N-[4-(6-アミノ-5-シアノ-2-{6-[3-(4-メチル-[1,4]ジアゼパン-1-イル)-3-オキソプロピル]ピリジン-2-イルメチルスルファニル}ピリミジン-4-イル)フェニル]アセトアミド。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005125880A JP4794200B2 (ja) | 2004-04-30 | 2005-04-25 | 4−アミノ−5−シアノピリミジン誘導体 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004135999 | 2004-04-30 | ||
JP2004135999 | 2004-04-30 | ||
JP2005125880A JP4794200B2 (ja) | 2004-04-30 | 2005-04-25 | 4−アミノ−5−シアノピリミジン誘導体 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005336168A true JP2005336168A (ja) | 2005-12-08 |
JP2005336168A5 JP2005336168A5 (ja) | 2008-05-01 |
JP4794200B2 JP4794200B2 (ja) | 2011-10-19 |
Family
ID=35490113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005125880A Expired - Fee Related JP4794200B2 (ja) | 2004-04-30 | 2005-04-25 | 4−アミノ−5−シアノピリミジン誘導体 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4794200B2 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008153182A1 (ja) * | 2007-06-15 | 2008-12-18 | Mitsubishi Tanabe Pharma Corporation | モルホリン誘導体 |
JP2011509924A (ja) * | 2009-02-03 | 2011-03-31 | 大塚製薬株式会社 | 新規なシアノピリミジン誘導体 |
JP2011513445A (ja) * | 2008-03-11 | 2011-04-28 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | ヘテロアリール置換ジシアノピリジン類およびそれらの使用 |
JP2012046513A (ja) * | 2010-07-30 | 2012-03-08 | Otsuka Pharmaceut Co Ltd | 医薬組成物 |
CN109651358A (zh) * | 2017-10-11 | 2019-04-19 | 上海迪诺医药科技有限公司 | 4-氨基吡啶衍生物、其药物组合物、制备方法及应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002070485A1 (de) * | 2001-03-07 | 2002-09-12 | Bayer Aktiengesellschaft | Substituierte 2-thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre verwendung als adenosinrezeptor-selektive liganden |
WO2003008384A1 (de) * | 2001-07-16 | 2003-01-30 | Bayer Healthcare Ag | Substituierte 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre verwendung als adenosinrezeptor-selektive liganden |
JP2003206230A (ja) * | 2002-01-10 | 2003-07-22 | Yamanouchi Pharmaceut Co Ltd | シアノヘテロ環誘導体又はその塩 |
JP2003523380A (ja) * | 2000-02-25 | 2003-08-05 | エフ.ホフマン−ラ ロシュ アーゲー | アデノシン受容体モジュレーター |
-
2005
- 2005-04-25 JP JP2005125880A patent/JP4794200B2/ja not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003523380A (ja) * | 2000-02-25 | 2003-08-05 | エフ.ホフマン−ラ ロシュ アーゲー | アデノシン受容体モジュレーター |
WO2002070485A1 (de) * | 2001-03-07 | 2002-09-12 | Bayer Aktiengesellschaft | Substituierte 2-thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre verwendung als adenosinrezeptor-selektive liganden |
WO2003008384A1 (de) * | 2001-07-16 | 2003-01-30 | Bayer Healthcare Ag | Substituierte 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre verwendung als adenosinrezeptor-selektive liganden |
JP2003206230A (ja) * | 2002-01-10 | 2003-07-22 | Yamanouchi Pharmaceut Co Ltd | シアノヘテロ環誘導体又はその塩 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008153182A1 (ja) * | 2007-06-15 | 2008-12-18 | Mitsubishi Tanabe Pharma Corporation | モルホリン誘導体 |
JP5368304B2 (ja) * | 2007-06-15 | 2013-12-18 | 田辺三菱製薬株式会社 | モルホリン誘導体 |
US8975252B2 (en) | 2007-06-15 | 2015-03-10 | Shanghai Pharmaceuticals Holding Co., Ltd. | Morpholine derivative |
JP2011513445A (ja) * | 2008-03-11 | 2011-04-28 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | ヘテロアリール置換ジシアノピリジン類およびそれらの使用 |
JP2011509924A (ja) * | 2009-02-03 | 2011-03-31 | 大塚製薬株式会社 | 新規なシアノピリミジン誘導体 |
JP2012046513A (ja) * | 2010-07-30 | 2012-03-08 | Otsuka Pharmaceut Co Ltd | 医薬組成物 |
CN109651358A (zh) * | 2017-10-11 | 2019-04-19 | 上海迪诺医药科技有限公司 | 4-氨基吡啶衍生物、其药物组合物、制备方法及应用 |
CN109651358B (zh) * | 2017-10-11 | 2023-04-07 | 上海迪诺医药科技有限公司 | 4-氨基吡啶衍生物、其药物组合物、制备方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
JP4794200B2 (ja) | 2011-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5201817B2 (ja) | 医薬組成物 | |
US7989446B2 (en) | 4-amino 5-cyanopyrimidine derivatives | |
CN102712624B (zh) | 吲哚化合物及其制药用途 | |
JP3989444B2 (ja) | 新規な化合物 | |
TWI532727B (zh) | 吡羧醯胺化合物 | |
KR20210040368A (ko) | 사이클린 의존성 키나제의 억제제 | |
CN106456619A (zh) | 作为irak4抑制剂的二环杂环衍生物 | |
NZ566862A (en) | Diarylamine-containing compounds and compositions, and their use as modulators of C-kit receptors | |
JP5753625B2 (ja) | mGluR5モジュレーターとしての5−(フェニル/ピリジニル−エチニル)−2−ピリジン/2−ピリミジン−カルボキサミド | |
WO2007114323A1 (ja) | アミノピロリジン化合物 | |
JP2003012653A (ja) | キナゾリン誘導体 | |
KR20070113225A (ko) | 히스타민 h3 수용체에 대해 친화성을 갖는 융합된 티아졸유도체 | |
JP4794200B2 (ja) | 4−アミノ−5−シアノピリミジン誘導体 | |
EP3821947A1 (en) | Heterocyclic trpml1 agonists | |
JP4705575B2 (ja) | iNOS阻害剤としてのクマリン類 | |
JP2002530378A (ja) | Nk−2およびnk−3受容体リガンドとしてのキノリン誘導体 | |
JPH07330777A (ja) | チエノ[3,2−d]ピリミジン−4−オン誘導体 | |
JP5760005B2 (ja) | 新規(複素環/テトラヒドロピリジン)−(ピペラジニル)−1−アルカノンおよび(複素環/ジヒドロピロリジン)−(ピペラジニル)−1−アルカノン誘導体、並びにp75阻害剤としてのこれらの使用 | |
US20160009697A1 (en) | Pyridine derivatives as 5-ht6 receptor antagonists | |
WO2019097282A1 (en) | Isoindoline derivatives for the treatment of cns diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080313 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080313 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110510 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110609 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110705 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110726 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4794200 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140805 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |